<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_Q5DY5DZ">Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease</title>
				<funder>
					<orgName type="full">Abbott Diabetes Care</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100011946</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Ó The Author(s) 2023</p>
				</availability>
				<date type="published" when="2023-06-16">June 16, 2023</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Tomasz</forename><surname>Klupa</surname></persName>
							<email>tomasz.klupa@uj.edu.pl</email>
						</author>
						<author>
							<persName><forename type="first">Czupryniak</forename><surname>Leszek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dzida</forename><surname>Grzegorz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Fichna</forename><surname>Piotr</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jarosz-Chobot</forename><surname>Przemyslawa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gumprecht</forename><surname>Janusz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mysliwiec</forename><surname>Malgorzata</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Szadkowska</forename><surname>Agnieszka</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bomba-Opon</forename><surname>Dorota</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Czajkowski</forename><surname>Krzysztof</surname></persName>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Maciej</surname></persName>
						</author>
						<author>
							<persName><surname>Malecki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Dorota</surname></persName>
						</author>
						<author>
							<persName><surname>Zozulinska-Ziolkiewicz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">M T</forename><surname>Malecki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Czupryniak</surname></persName>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Dzida</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Fichna</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Jarosz-Chobot</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Gumprecht</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Mysliwiec</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Szadkowska</surname></persName>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Czajkowski</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Zozulinska-Ziolkiewicz</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Department of Metabolic Diseases , Jagiellonian University Medical College , Krakow , Poland</note>
								<orgName type="department">Department of Metabolic Diseases</orgName>
								<orgName type="institution">Jagiellonian University Medical College</orgName>
								<address>
									<settlement>Krakow</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">Department of Diabetology and Internal Medicine , Medical University of Warsaw , Warsaw , Poland</note>
								<orgName type="department">Department of Diabetology and Internal Medicine</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Department of Internal Diseases , Medical University of Lublin , Lublin , Poland</note>
								<orgName type="department">Department of Internal Diseases</orgName>
								<orgName type="institution">Medical University of Lublin</orgName>
								<address>
									<settlement>Lublin</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Department of Pediatric Diabetes and Obesity , Poznan University of Medical Sciences , Poznan , Poland</note>
								<orgName type="department">Department of Pediatric Diabetes and Obesity</orgName>
								<orgName type="institution">Poznan University of Medical Sciences</orgName>
								<address>
									<settlement>Poznan</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">Department of Children&apos;s Diabetology , Medical University of Silesia , Katowice , Poland</note>
								<orgName type="department">Department of Children&apos;s Diabetology</orgName>
								<orgName type="institution">Medical University of Silesia</orgName>
								<address>
									<settlement>Katowice</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Department of Internal Medicine, Diabetology and Nephrology , Medical University of Silesia , Katowice , Poland</note>
								<orgName type="department">Department of Internal Medicine, Diabetology and Nephrology</orgName>
								<orgName type="institution">Medical University of Silesia</orgName>
								<address>
									<settlement>Katowice</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Department of Pediatrics, Diabetology and Endocrinology , Medical University of Gdansk , Gdansk , Poland</note>
								<orgName type="department">Department of Pediatrics, Diabetology and Endocrinology</orgName>
								<orgName type="institution">Medical University of Gdansk</orgName>
								<address>
									<settlement>Gdansk</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Department of Pediatrics, Diabetology, Endocrinology and Nephrology , Medical University of Lodz , Lodz , Poland</note>
								<orgName type="department">Department of Pediatrics, Diabetology, Endocrinology and Nephrology</orgName>
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<note type="raw_affiliation">Bomba-Opon 1st Department of Obstetrics and Gynecology , Medical University of Warsaw , Warsaw , Poland</note>
								<orgName type="department" key="dep1">Bomba-Opon</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>2nd</label> Department of Obstetrics and Gynecology , Medical University of Warsaw , Warsaw , Poland</note>
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<note type="raw_affiliation">Department of Internal Medicine and Diabetology , Poznan University of Medical Science , Poznan , Poland</note>
								<orgName type="department">Department of Internal Medicine and Diabetology</orgName>
								<orgName type="institution">Poznan University of Medical Science</orgName>
								<address>
									<settlement>Poznan</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_fKhUKxp">Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2023-06-16">June 16, 2023</date>
						</imprint>
					</monogr>
					<idno type="MD5">5F923D027EBCFEB8A80A46A106E30594</idno>
					<idno type="DOI">10.1007/s13300-023-01431-3</idno>
					<note type="submission">Received: April 25, 2023 / Accepted: May 31, 2023 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T06:07+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_qYsxcy3">Continuous glucose monitoring</term>
					<term xml:id="_WzwjwdY">Hospital inpatients</term>
					<term xml:id="_R22Wfxe">Pregnancy</term>
					<term xml:id="_Mr5CX8d">Type 2 diabetes</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_5ZbVfJN"><p xml:id="_qFvMMHR"><s xml:id="_x4GCHXJ">Application of continuous glucose monitoring (CGM) has moved diabetes care from a reactive to a proactive process, in which a person with diabetes can prevent episodes of hypoglycemia or hyperglycemia, rather than taking action only once low and high glucose are detected.</s><s xml:id="_7zRT8Vz">Consequently, CGM devices are now seen as the standard of care for people with type 1 diabetes mellitus (T1DM).</s><s xml:id="_6n2q9Y9">Evidence now supports the use of CGM in people with type 2 diabetes mellitus (T2DM) on any treatment regimen, not just for those on insulin therapy.</s><s xml:id="_FPGTrf3">Expanding the application of CGM to include all people with T1DM or T2DM can support effective intensification of therapies to reduce glucose exposure and lower the risk of complications and hospital admissions, which are associated with high healthcare costs.</s><s xml:id="_HJF3WWW">All of this can be achieved while minimizing the risk of hypo-</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="21" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="22" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="23" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="24" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="25" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="26" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_P4HMkXc">INTRODUCTION</head><p xml:id="_ZUk2GXe"><s xml:id="_GwJwYch">The landscape of treating and managing diabetes has been transformed over the past decade by the increased availability and application of continuous glucose monitoring (CGM) technology, which provides people with diabetes and their healthcare professionals (HCPs) with on-demand glucose information.</s><s xml:id="_sFZpm79">This includes not only the current glucose reading for the user, at any time of day, but also important information on whether their glucose levels are stable, rising, or falling.</s><s xml:id="_yQzASXF">The glucose data collected by CGM devices is also used to generate important patterns and trends that can be analyzed retrospectively to understand the overall glycemic balance of the user, and that can be used to guide therapeutic decisions on diabetes care.</s><s xml:id="_SKqqAHj">These capabilities go far beyond the limitations of traditional fingerprick self-monitoring of blood glucose (SMBG) testing, which is often painful for the user and provides only a one-time snapshot of glucose levels when a test is conducted.</s><s xml:id="_rsWas7J">The use of CGM also enables parents and caregivers to monitor glucose levels in school-age children or elderly people remotely, using smartphone apps, which allows an additional level of care for people with diabetes as they participate in different activities.</s></p><p xml:id="_sZ4USnv"><s xml:id="_8r4gqrD">Commercially available CGM devices provide a measurement of glucose levels in the interstitial fluid (ISF) in the subcutaneous space <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>, either using a thin sensor filament that is inserted into the subcutaneous space (transcutaneous) or by insertion of the sensor itself into the subcutaneous tissue in the upper arm (implantable).</s><s xml:id="_X8XJZjD">Glucose readings are transmitted wirelessly at 1-5-min intervals to a reader or a smartphone app.</s><s xml:id="_tGPWYMa">Some CGM devices transmit glucose data only when the user scans their sensor with a reader or smartphone app.</s><s xml:id="_kjX94dV">This is referred to as intermittently scanned CGM (isCGM) or as FLASH glucose monitoring, referring in both cases to the FreeStyle Libre system.</s></p><p xml:id="_tPgXQUT"><s xml:id="_FGq5KdC">The accuracy of CGM devices in comparison with reference plasma glucose measurements is well validated <ref type="bibr" target="#b2">[3]</ref>, such that several CGM devices are authorized by regulatory authorities to replace fingerstick SMBG testing for making diabetes treatment decisions, including insulin dosing (non-adjunctive use).</s><s xml:id="_nrkpuDh">In addition, a specific category of Class II device type, identified as an integrated CGM (iCGM) device <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>, has been created by the US Food and Drug Administration (FDA) for CGM devices that are suitable for use with certain digitally connected medical devices, including automated insulin delivery (AID) systems.</s></p><p xml:id="_RFzP7cZ"><s xml:id="_gw8DCzz">Currently available transcutaneous systems have sensors that have wear times from 6 to 14 days <ref type="bibr" target="#b5">[6]</ref>, after which a new sensor is applied.</s><s xml:id="_N5t9EcS">Implantable systems currently transmit glucose data for up to 180 days before replacement <ref type="bibr" target="#b6">[7]</ref>.</s><s xml:id="_AkBj8Q7">CGM sensors may be factory calibrated <ref type="bibr" target="#b5">[6]</ref> or calibrated using a code provided with each sensor <ref type="bibr" target="#b7">[8]</ref>.</s><s xml:id="_wgUSsp9">Alternatively, CGM sensors can require users to perform daily calibration using SMBG tests <ref type="bibr" target="#b8">[9]</ref>.</s></p><p xml:id="_mnB8YGx"><s xml:id="_42p4w2k">An important distinction is that CGM systems can be configured to operate as personal CGM devices, in which the user is able to see their glucose values on demand and to take action based on these values, or as professional CGM systems, which are blinded for the user and transmit glucose data that can be reviewed only by their diabetes HCP <ref type="bibr" target="#b9">[10]</ref>.</s><s xml:id="_Vfme4KC">Here we review the evidence for wider application of CGM devices in the care of people with diabetes or glycemic dysregulation.</s><s xml:id="_ShzJAVz">In places the evidence is limited and a statement of unmet research needs is provided in Supplementary Table <ref type="table">1</ref>.</s><s xml:id="_ENwzNqv">All interpretations and recommendations meet ethics guidelines and conform with the 1964 Declaration of Helsinki.</s><s xml:id="_cxGQxNF">This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ATRCnfm">BENEFITS OF USING CGM IN DAILY DIABETES CARE</head><p xml:id="_nRexFsg"><s xml:id="_NR53hQT">A considerable body of evidence supports the use of CGM to transform health outcomes and quality of life for people with diabetes.</s><s xml:id="_hQFgz97">In reality, this is paradigm shift in the treatment of people with diabetes, moving from reactive responses to the proactive prevention of high and low glucose levels.</s></p><p xml:id="_7rQUwb8"><s xml:id="_NTZRYcP">When compared with SMBG, the use of CGM devices has been associated with lowered HbA1c in children and adults with type 1 diabetes mellitus (T1DM) <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr">[17]</ref><ref type="bibr">[18]</ref>, and in adults with type 2 diabetes mellitus (T2DM) treated either with insulin or a non-insulin therapy <ref type="bibr">[19]</ref><ref type="bibr">[20]</ref><ref type="bibr">[21]</ref><ref type="bibr" target="#b16">[22]</ref>.</s><s xml:id="_Eb2czau">Both in T1DM and T2DM, use of CGM is associated with reduced risk of hypoglycemia <ref type="bibr" target="#b17">[23]</ref><ref type="bibr" target="#b18">[24]</ref><ref type="bibr" target="#b19">[25]</ref>.</s><s xml:id="_bMqB2MG">Prospective trials have typically documented these glycemic benefits over periods up to 12 months; however, the COMISAIR prospective study demonstrated a persistent effect of the Dexcom G4 real-time CGM system over 3 years in adults with T1DM <ref type="bibr" target="#b13">[14]</ref>.</s><s xml:id="_V7emyrb">A second extended study of adults with T1DM started on CGM within 12 months of their diagnosis found that reductions in HbA1c were persistent with CGM use over a 7-year period <ref type="bibr" target="#b20">[26]</ref>.</s><s xml:id="_DqQVk7j">A metaanalysis of 75 real-world studies involving the FreeStyle Libre system indicates that the glycemic benefits of using CGM persist for at least 2 years in adults with T2DM <ref type="bibr" target="#b21">[27]</ref>.</s><s xml:id="_Zaw6rvW">These evidence-based benefits of using CGM devices have confirmed their efficacy and place in the standard of care for people with T1DM or T2DM on insulin <ref type="bibr" target="#b22">[28]</ref><ref type="bibr" target="#b24">[29]</ref><ref type="bibr" target="#b25">[30]</ref><ref type="bibr" target="#b26">[31]</ref>.</s></p><p xml:id="_9sMBQu3"><s xml:id="_gEEX4Ut">Importantly, CGM-derived metrics are now standardized for reporting <ref type="bibr" target="#b22">[28]</ref><ref type="bibr" target="#b24">[29]</ref><ref type="bibr" target="#b25">[30]</ref>.</s><s xml:id="_EysaH6Z">Thus, using CGM compared to SMBG alone is associated with more time in range (TIR) with a glucose level of 70-180 mg/dL, less time above range (TAR) in hyperglycemia with a glucose level greater than 180 mg/dL, and less time below range (TBR) in hypoglycemia with a glucose level lower than 70 mg/dL, including nocturnal hypoglycemia, in people with T1DM or T2DM <ref type="bibr" target="#b17">[23]</ref><ref type="bibr" target="#b18">[24]</ref><ref type="bibr" target="#b19">[25]</ref><ref type="bibr" target="#b27">32]</ref>.</s><s xml:id="_dsQ3KBJ">CGM users also have less glucose variability, improved quality of life <ref type="bibr" target="#b28">[33]</ref><ref type="bibr" target="#b29">[34]</ref><ref type="bibr" target="#b30">[35]</ref>, and have fewer hospital admissions for acute diabetes events such as diabetic ketoacidosis (DKA) and severe hypoglycemia <ref type="bibr" target="#b31">[36]</ref><ref type="bibr" target="#b32">[37]</ref><ref type="bibr" target="#b33">[38]</ref><ref type="bibr" target="#b34">[39]</ref><ref type="bibr" target="#b35">[40]</ref>.</s></p><p xml:id="_8y5z7wy"><s xml:id="_eVUaMrJ">Along with the well-documented benefits for users and HCPs, there are also benefits for parents, carers, and partners of people with diabetes, the majority of whom feel positive about CGM <ref type="bibr" target="#b36">[41]</ref>.</s><s xml:id="_6HHK49X">Parents of children and adolescents with T1DM report improved quality of life and emotional well-being after their children started CGM <ref type="bibr" target="#b37">[42,</ref><ref type="bibr" target="#b38">43]</ref>.</s><s xml:id="_gwZzMFN">The reduced fear of hypoglycemia, especially at night, is a driver of improved well-being <ref type="bibr" target="#b39">[44,</ref><ref type="bibr" target="#b40">45]</ref>.</s><s xml:id="_gBuBvCK">Equally, using CGM is reported to reduce diabetes-specific conflict in families and facilitated parental involvement in diabetes management <ref type="bibr" target="#b38">[43]</ref>.</s><s xml:id="_wFtyrGu">Carers for frail, older people with T1DM or T2DM also report greater ease of managing diabetes in this vulnerable group, with reduced concerns about hypoglycemia <ref type="bibr" target="#b41">[46]</ref>.</s><s xml:id="_BYUpC8y">The ability to share glucose data is also seen as a positive aspect of using CGM by older adults and their caregivers <ref type="bibr" target="#b42">[47]</ref>.</s><s xml:id="_XB92Pjq">All of these benefits are also reported by partners or spouses of people with diabetes <ref type="bibr" target="#b43">[48]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JVgN9k4">Challenges for Using CGM in Diabetes Management</head><p xml:id="_74vhMjC"><s xml:id="_a9Mw89S">As with all medical technologies, using CGM systems is accompanied by challenges.</s><s xml:id="_6DsrSjM">Although current CGM devices are accurate across all ISF glucose ranges within 30-60 min after they are activated, they may be affected by a small number of substances, such as paracetamol, hydroxyurea, or high doses of vitamin C <ref type="bibr" target="#b44">[49]</ref>.</s><s xml:id="_gycgA3h">Because CGM sensors are on-body devices, they may be subject to physical stresses that can dislodge them or transiently affect their performance, such as artifacts from the user lying in a position that compresses the sensor and the tissue around it <ref type="bibr" target="#b45">[50]</ref>.</s><s xml:id="_enjjz2e">CGM sensors are also visible clues that the wearer has diabetes, which can become a focus for conscious or unconscious judgement and stigmatization, even from family and their HCPs <ref type="bibr" target="#b46">[51]</ref>.</s><s xml:id="_CA6z8KV">Possibly the biggest challenge of using CGM is the huge amount of data that it provides, both during daily use and for review with HCPs.</s><s xml:id="_jACBAcw">The user may overreact to changes in visible glucose levels or trends, with consequent micromanagement.</s><s xml:id="_3J3pQyh">The task of reviewing ambulatory glucose profile (AGP) reports can also be daunting, requiring education for users and HCPs (see below).</s><s xml:id="_hB5BkyK">However, research with CGM users and HCPs indicates that these challenges are not a major barrier to successful implementation, either for people with diabetes or their HCPs <ref type="bibr" target="#b37">[42]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RkWFQ5H">CGM IN GUIDELINES FOR DIABETES MANAGEMENT</head><p xml:id="_6VX3UXv"><s xml:id="_ZWVtUbv">Use of CGM has rapidly become an accepted part of clinical guidelines for the treatment of diabetes.</s><s xml:id="_CBAHxCx">In the UK, the National Institute for Health and care Excellence (NICE) recommended access to isCGM for subgroups of people with T1DM on insulin therapy as early as 2017 <ref type="bibr" target="#b47">[52]</ref> and current guidelines now recommend either isCGM or real-time CGM for all adults and children with T1DM and people with T2DM on intensive insulin therapy <ref type="bibr" target="#b48">[53]</ref><ref type="bibr">[54]</ref><ref type="bibr" target="#b50">[55]</ref>.</s><s xml:id="_bgERAeE">Diabetes technology was included in the American Diabetes Association (ADA) standards of medical care in diabetes for the first time only in 2019, at which point stand-alone CGM was suggested for ''consideration'' in children and adolescents with T1DM and indicated as a ''useful tool'' for adults with T1DM <ref type="bibr" target="#b51">[56]</ref>.</s><s xml:id="_gWQfeyf">By 2022, the same guidelines simply state: ''Use of CGM devices should be considered from the outset of the diagnosis of diabetes that requires insulin management'' <ref type="bibr" target="#b52">[57]</ref>.</s><s xml:id="_QGWyuFt">This has been echoed in the consensus guidelines for management of T1DM from the European Association for the Study of Diabetes (EASD) and the ADA <ref type="bibr" target="#b53">[58]</ref>, which indicate that CGM is the preferred option for glucose monitoring in newly diagnosed T1DM in adults, and should be considered for adults with established T1DM, even if they are meeting glycemic targets.</s></p><p xml:id="_t2addrR"><s xml:id="_fdXcan5">While recognizing and supporting the value of using CGM for children with T1DM <ref type="bibr" target="#b54">[59,</ref><ref type="bibr" target="#b55">60]</ref>, the International Society for Pediatric and Adolescent Diabetes (ISPAD) does not make a specific recommendation to initiate CGM at the point of diagnosis for children with T1DM.</s><s xml:id="_KDreFzV">We propose that this step should be taken, even in low-resource settings <ref type="bibr" target="#b56">[61]</ref>.</s><s xml:id="_N4M2Nfv">The long-term benefits of proactive glucose control with CGM for children with T1DM are compelling.</s></p><p xml:id="_cZWazG4"><s xml:id="_aam2Kh5">Similarly, CGM can be used as part of a targeted screening and monitoring strategy in individuals identified as at-risk for T1DM as a consequence of family history or detectable islet autoantibodies <ref type="bibr" target="#b57">[62]</ref>.</s><s xml:id="_syzKSCG">As they progress to stage 1, stage 2, and pre-symptomatic stage 3 in T1DM, use of CGM can detect abnormal glucose metabolism as individuals progress to stage 2. Proactive screening in this way can reduce the incidence of DKA and rates of hospitalization as symptoms become overt <ref type="bibr" target="#b57">[62]</ref>.</s></p><p xml:id="_CwVRvdJ"><s xml:id="_r36kR5A">The 2022 ADA/EASD consensus guidelines for management of hyperglycemia in T2DM <ref type="bibr" target="#b58">[63]</ref> also recommend the use of CGM for people with T2DM treated with insulin.</s><s xml:id="_jCZtQsz">An expert consensus group from the American Association of Clinical Endocrinology (AACE) published guidelines in 2021 that strongly recommended CGM for all persons with diabetes treated with intensive insulin therapy, defined as three or more injections of insulin per day or the use of an insulin pump <ref type="bibr" target="#b59">[64]</ref>.</s><s xml:id="_su4Mwrt">In this context, real-time CGM was recommended over isCGM for people with diabetes and problematic hypoglycemia, because of the value of low-glucose alarms.</s><s xml:id="_yWE3Y8J">However, second-generation isCGM systems already provided low-and high-glucose alarms at the point this recommendation was made <ref type="bibr" target="#b60">[65]</ref>, underlining the rapid pace of change in this aspect of diabetes care.</s></p><p xml:id="_ZhY63V4"><s xml:id="_qqgW6Wj">Most recently, Asia-Pacific (APAC) consensus recommendations <ref type="bibr" target="#b61">[66]</ref> for the application of CGM in diabetes include initiating CGM as soon as possible after a diagnosis of T1DM and for people with T2DM on intensive insulin therapy and suboptimal glycemic control or high risk of problematic hypoglycemia.</s><s xml:id="_E5sQJXe">The APAC guidance also makes clear statements regarding daily or intermittent use of CGM for people with T2DM during Ramadan, for frail, older individuals with T2DM, pregnant women with pregestational T2DM, and women with gestational diabetes mellitus (GDM).</s><s xml:id="_ye4mA8Y">Notably, the APAC guidelines include a process for interpreting AGP reports in APAC settings along with targets for core CGM metrics in adults with T1DM, T2DM, and in pregnancy for women with T1DM or T2DM <ref type="bibr" target="#b61">[66]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Pb4cyXZ">CGM MAY BE USED ON A DAY-TO-DAY OR INTERMITTENT BASIS</head><p xml:id="_na5rnVq"><s xml:id="_qYccBxF">Children and adult users of CGM in the management of T1DM are recommended to wear a glucose sensor on a daily basis, since clinical evidence in support of CGM has been collected in this way and reflects the need for people with T1DM on intensive insulin therapy to maintain control over fluctuating glucose levels and avoid potentially harmful episodes of hypoglycemia <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b18">24,</ref><ref type="bibr" target="#b62">67]</ref>.</s><s xml:id="_p5BXxUM">CGM systems provide on-demand glucose readings alongside valuable information on the direction and rate of change (ROC) of glucose, indicated by trend arrows <ref type="bibr" target="#b63">[68]</ref>.</s><s xml:id="_hWx2847">For people with T2DM on insulin therapy, the risks of hypoglycemia are also considerable <ref type="bibr" target="#b64">[69]</ref> and daily use is supported by evidence <ref type="bibr">[20,</ref><ref type="bibr" target="#b19">25]</ref> and also recommended in guidelines (see above).</s></p><p xml:id="_r2sdW6P"><s xml:id="_Bp7DqNf">Daily use of isCGM or real-time CGM is now typically reimbursed by healthcare systems as part of care for people with T1DM and increasingly for people with T2DM on intensive insulin therapy.</s><s xml:id="_HjKH8qk">The benefits of using CGM in people with T2DM on basal-only regimens or non-insulin therapies are also demonstrated <ref type="bibr">[21,</ref><ref type="bibr" target="#b16">22,</ref><ref type="bibr" target="#b35">40,</ref><ref type="bibr" target="#b65">70,</ref><ref type="bibr" target="#b66">71]</ref>, but access to CGM is limited for these and other groups of people with diabetes because of the need to control costs, such that recommending daily use is impractical for most health services.</s><s xml:id="_JFkABpY">Therefore, the intermittent use of CGM devices can be recommended as a practical alternative that is more realistic from a cost-impact perspective, in which the CGM device is used only for pre-specified periods during diabetes care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gQks2zw">Benefits of Intermittent Use of CGM</head><p xml:id="_MUhyEYD"><s xml:id="_5SGd6ac">Intermittent use of CGM for people with T2DM has been proposed previously <ref type="bibr" target="#b67">[72]</ref>, to support management of poorly controlled patients on any therapeutic regimen, and is also recommended in ADA guidance of the use of technology in diabetes <ref type="bibr" target="#b52">[57]</ref>.</s><s xml:id="_emTYQcU">Use of intermittent or professional CGM should always be followed by a review with the person with diabetes, including any education required as part of changes to medication and/or lifestyle <ref type="bibr" target="#b52">[57]</ref>.</s><s xml:id="_zqNjDEQ">There is an unmet need for further supporting evidence on this aspect of CGM use.</s></p><p xml:id="_shAzvDT"><s xml:id="_Sp5FT8V">A systematic review of 11 studies involving 5542 patients, 90% not on intensive insulin therapy, concluded that intermittent use of CGM was associated with reductions in HbA1c and body weight, as well as improved adherence to dietary plans and physical activity <ref type="bibr" target="#b68">[73]</ref>.</s><s xml:id="_rwGU7C4">Periodic use of CGM in people with T2DM not on insulin therapy has shown reduced HbA1c and improved TIR <ref type="bibr" target="#b69">[74,</ref><ref type="bibr" target="#b70">75]</ref>.</s><s xml:id="_MKcUCxN">These changes are most significant for people with T2DM using CGM for 10 days at 3-month intervals, who also had a mean SMBG use at a frequency of 1.5 tests per day or more <ref type="bibr" target="#b70">[75]</ref> over a 6-month prospective study period.</s><s xml:id="_MsJFpUa">In this study the intervention with CGM was non-blinded, allowing participants to see their glucose readings and trends.</s></p><p xml:id="_KNVvEBr"><s xml:id="_erGcVzF">The use of professional CGM, in which the CGM data is only available to the HCP, has also been tested in people with T2DM not on insulin therapy.</s><s xml:id="_tyXhYQ2">A 2008 randomized controlled trial (RCT) demonstrated that a single 3-day application of blinded CGM, with follow-up review and education with a HCP, can lead to changes in behavior and reduced HbA1c in people with T2DM failing on non-insulin therapy <ref type="bibr" target="#b71">[76]</ref>.</s><s xml:id="_fmMUUac">Just as importantly, studies using blinded CGM even for 5 days have confirmed that approximately 50% of people with T2DM, including those on non-insulin therapy, experience frequent mild or clinically significant hypoglycemia <ref type="bibr" target="#b72">[77]</ref> and this is asymptomatic in most cases.</s><s xml:id="_W7ghqED">Such insights can allow for treatment adjustment focused on reducing the risk of hypoglycemia alongside overall glycemic control.</s></p><p xml:id="_wgkhexg"><s xml:id="_Gte2d7N">Intermittent application of CGM systems, either as part of unblinded or blinded use, is able to deliver glycemic information of value both to the person with T2DM and to their HCP, thereby facilitating improved glycemic control.</s><s xml:id="_wycAYmY">Of clinical importance, this can be maintained through changes to lifestyle and periodic medication review and adjustment.</s><s xml:id="_b2FPCgQ">No studies have examined the long-term application of intermittent CGM in T2DM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZyadMWa">Adapting Diabetes Care to the Cost of CGM Technology</head><p xml:id="_Cma74aX"><s xml:id="_AGV4KRf">Evidence on the cost-effectiveness of using CGM devices in diabetes care is limited.</s><s xml:id="_MTDUbtn">The per-unit costs of CGM sensors are higher than SMBG test strips and meters, which has created a perceived barrier to wider adoption.</s><s xml:id="_tS49FsY">However, the long-term costs for daily CGM use, when factoring in savings against strip usage and costs for medical consultation and care of diabetes complications, are modelled as being cost-effective for people with T1DM <ref type="bibr" target="#b73">[78]</ref><ref type="bibr" target="#b74">[79]</ref><ref type="bibr" target="#b75">[80]</ref><ref type="bibr" target="#b76">[81]</ref>.</s><s xml:id="_fdJBXuH">In these analyses, much of the value assigned to CGM use was in the saved costs for reduced cumulative rates of diabetes complications and deaths in cardiovascular disease, ulcers and amputations, and renal disease.</s><s xml:id="_TsMJvFB">Although these complications are all part of long-term health outcomes in T2DM, a formal assessment for the cost impact of T2DM over the lifetime horizon is an unmet need.</s><s xml:id="_sdrjUrk">However, at least two studies have demonstrated that intermittent use of CGM in people with T2DM not on prandial insulin is a cost-effective intervention <ref type="bibr" target="#b77">[82,</ref><ref type="bibr" target="#b78">83]</ref>, again based on lifetime reductions in treatment costs for diabetes complications.</s><s xml:id="_V2rj54J">The periodic use of CGM in each of these studies was not similar, one at a high frequency <ref type="bibr" target="#b77">[82]</ref>, the other at a low frequency <ref type="bibr" target="#b78">[83]</ref>, suggesting that the optimal period between applications and glycemic assessment requires further study.</s></p><p xml:id="_CnKWSkp"><s xml:id="_7Jcf92S">In order to minimize costs to healthcare providers we would argue that the most costeffective use of intermittent CGM would favor the use of the FreeStyle Libre 2 or FreeStyle Libre 3 system.</s><s xml:id="_FmmywR8">Glycemic outcomes data for the FreeStyle Libre system are comparable with those of real-time CGM systems, including reductions in HbA1c, improvements in TIR, and reductions in hypoglycemia <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b19">25,</ref><ref type="bibr" target="#b79">84]</ref>.</s><s xml:id="_YP4cxWa">The FreeStyle Libre sensors are factory calibrated and need no daily fingerstick calibration, which makes them suited to periodic application and adherence with use.</s><s xml:id="_JbvWeYs">They also may be more suited to intermittent use as they are easy to apply and do not require a transmitter, such that users have less to self-manage during occasional use.</s><s xml:id="_Q6qxGNT">Critically, they have the lowest acquisition cost among currently available CGM devices and the longest on-body wear time, with each sensor lasting 14 days.</s><s xml:id="_RegZVfa">The FreeStyle Libre 2 and FreeStyle Libre 3 systems are also enabled with optional alarms that may reinforce the educational value for the user during 14-day intermittent use.</s><s xml:id="_4429ZHQ">Freestyle Libre sensors can also be used as part of professional CGM, although different healthcare territories have selective availability of this option.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EnuWC9H">OPTIMIZING THE VALUE OF CGM IN MODERN DIABETES CARE</head><p xml:id="_e97rVjf"><s xml:id="_59DtsRg">Diabetes care using CGM has typically focused on addressing the unmet needs for day-to-day glycemic control.</s><s xml:id="_6SDBffN">This has meant focusing on reducing HbA1c for people with poorly controlled diabetes, as well as reducing the risks of symptomatic and severe hypoglycemia for people on insulin or insulinotropic therapies.</s><s xml:id="_AvuYAqD">There is sufficient data to support the use of CGM in a much wider group of people with diabetes such that it meets a range of needs at different times throughout their lives with diabetes.</s><s xml:id="_DfqbDzK">These are all separate from the management of T1DM or T2DM on insulin therapy, in which daily use of CGM is indicated and supported by guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MqTFWmv">At the Point of Diagnosis of T2DM</head><p xml:id="_tVeKTEz"><s xml:id="_CfPwjFt">There are many pathophysiological changes to glucose homeostasis that result in persistent hyperglycemia and a diagnosis of T2DM.</s><s xml:id="_DtUgwCy">Ultimately, this also means that T2DM is a very heterogeneous disease <ref type="bibr" target="#b80">[85]</ref>.</s><s xml:id="_SG7eFcq">Over the last few years, analysis of glucose profiles for people with T2DM has suggested that some of this heterogeneity can be mapped to glucotypes, based on patient characteristics and CGM-defined glycemic metrics <ref type="bibr" target="#b80">[85,</ref><ref type="bibr" target="#b81">86]</ref>.</s><s xml:id="_Ne32b2R">It has been proposed that some of these glucotypes may be predictive of future complications <ref type="bibr" target="#b80">[85]</ref>.</s><s xml:id="_npX82Q5">At the time of diagnosis, it therefore makes sense to establish as much as possible about the baseline glycemic profile for any person with T2DM, such that a diabetes management plan can be put in place as early as possible that meets their individual treatment needs.</s><s xml:id="_qMUBJeE">Intermittent use of CGM should be used as soon possible after diagnosis to establish these baseline glucose parameters for each person with T2DM, against which subsequent treatment decisions may be compared and disease progression monitored.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6zP7Qzx">Monitoring Proactive Treatment Intensification</head><p xml:id="_jx52ctT"><s xml:id="_pn6XMXG">Clinical inertia is a term that defines the reticence of HCPs to initiate or intensify therapy for people with T2DM in a timely manner, as recommended by evidence-based clinical guidelines <ref type="bibr" target="#b82">[87]</ref><ref type="bibr" target="#b83">[88]</ref><ref type="bibr" target="#b84">[89]</ref>.</s><s xml:id="_zvnGsZz">Although a change of therapy in T2DM is indicated if HbA1c goals are not achieved after 3 months on the current regimen <ref type="bibr" target="#b85">[90]</ref>, reported times to treatment intensification are considerably higher, with the median time to treatment intensification after an above-target HbA1c test reading being measured in years rather than months <ref type="bibr" target="#b86">[91]</ref>, and this inertia may be considerably prolonged as the number of antidiabetic drugs in the treatment plan rises <ref type="bibr" target="#b86">[91]</ref>.</s><s xml:id="_HZEkmJ8">Such clinical inertia is linked to the increased incidence of microvascular and macrovascular disease in T2DM <ref type="bibr" target="#b87">[92,</ref><ref type="bibr" target="#b88">93]</ref>, as well as significantly increased costs related to diabetes complications <ref type="bibr" target="#b89">[94,</ref><ref type="bibr" target="#b90">95]</ref>.</s></p><p xml:id="_Rw2EYC6"><s xml:id="_nqwzBPF">It does not make sense to ignore the value of CGM as part of treatment intensification for people with T2D, particularly as fear of hypoglycemia is known to be a significant factor in clinical inertia for patients and clinicians alike <ref type="bibr" target="#b91">[96]</ref>.</s><s xml:id="_nnzSrWx">Use of CGM in people with T2DM on basal-only insulin is associated with improvements in HbA1c while reducing hypoglycemia <ref type="bibr">[19]</ref>.</s></p><p xml:id="_Aqspaa3"><s xml:id="_zm7NpKh">A retrospective analysis of large healthcare claims datasets indicate that use of a CGM device by people with T2DM is associated with more-timely treatment intensification compared to those using fingerprick SMBG testing alone <ref type="bibr" target="#b92">[97]</ref>.</s><s xml:id="_9FNTBmN">All treatment choices were facilitated in this analysis, including starting and intensifying insulin therapy.</s><s xml:id="_uf5bPcg">Although this analysis applied to people with T2DM on daily CGM use, it can be argued that intermittent use at the point of treatment intensification can support the same outcomes.</s><s xml:id="_MbnXtVA">A prospective study using professional CGM in 68 people with T2D on any treatment regimen <ref type="bibr" target="#b93">[98]</ref> showed that 14-days use of professional CGM in a primary care setting, followed by a review with the HCP and any treatment recommendations, is effective at lowering HbA1c, increasing TIR, and facilitating treatment intensification.</s><s xml:id="_eVjsZux">The improvement in glycemic management was accomplished by a combination of lifestyle counseling and medication intensification, rather than an increase in the number of medications.</s><s xml:id="_xspqjnM">Use of a second application of professional CGM after 3--6 months in a subset of participants was associated with more intensive treatment modification <ref type="bibr" target="#b94">[99]</ref>.</s><s xml:id="_HTGgnWP">Together with the data on cost-efficacy for intermittent CGM in T2DM <ref type="bibr" target="#b77">[82,</ref><ref type="bibr" target="#b78">83]</ref>, these data clearly indicate that intermittent CGM can be used to support treatment intensification in T2DM and this can be managed in a primary care or clinical pharmacy setting.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vAejkZX">CGM Coaching and Motivational Support for Behavioral Change in People with Diabetes</head><p xml:id="_zWzvWdB"><s xml:id="_Zh9dFQP">The glycemic benefits of intermittent CGM are connected to its impact on the overall behavior of people with T1DM or T2DM.</s><s xml:id="_hDc4BCH">Once they can see how the daily activities associated with diet, physical activity, and adherence to treatment affect glucose levels, it makes sense to adapt these activities even after the CGM has been withdrawn.</s><s xml:id="_fF8N8P5">Demonstrating this holistic effect in a study setting is not easy and there are only a small number that address this.</s><s xml:id="_UhK67Jp">Using isCGM has been linked to improved self-awareness of food consumption for people with T1DM, including increased confidence in food choices in relation to their expectations for diabetes management <ref type="bibr">[100]</ref>.</s></p><p xml:id="_CSPZ4b7"><s xml:id="_KjdSPGz">Lifestyle counseling following application of professional CGM was credited with the glycemic changes in people with T2DM, as much as medication intensification <ref type="bibr" target="#b93">[98]</ref>, and intermittent use of CGM has been associated with improved adherence to dietary plans, improved healthy eating, and physical activity <ref type="bibr" target="#b68">[73,</ref><ref type="bibr">101]</ref>.</s><s xml:id="_Nn5rHjs">When used as an adjunct to diabetes and lifestyle education for people with T2DM, intermittent CGM has resulted in greater improvements than education alone <ref type="bibr">[102]</ref>, and the use of motivational text messaging has been successful in promoting lifestyle changes and reduction of glycemia in people recently diagnosed with T2DM who used personal CGM for a limited time <ref type="bibr">[103]</ref>.</s><s xml:id="_pHUJFjv">We suggest therefore that such ''CGM coaching'' is a valid tool as part of the diabetes self-management education and support (DSMES) intervention that is identified as being as equally critical as pharmacological treatment for people with T2DM <ref type="bibr" target="#b58">[63]</ref>.</s><s xml:id="_gPK2PVn">Further objective research in this context is warranted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_CRUZEJu">CGM IS EFFECTIVE IN DAILY MANAGEMENT OF T2DM ON INSULIN REGIMENS</head><p xml:id="_eMfnEcD"><s xml:id="_3rAqErx">It is accepted that people with T2DM on intensive insulin therapy benefit from using CGM devices in the same way that has been shown for people with T1DM.</s><s xml:id="_kGySYc6">This includes reduced HbA1c <ref type="bibr">[20,</ref><ref type="bibr" target="#b79">84]</ref>, reduced hypoglycemia <ref type="bibr" target="#b19">[25,</ref><ref type="bibr" target="#b79">84]</ref>, and fewer acute diabetes events leading to hospital admission <ref type="bibr" target="#b33">[38,</ref><ref type="bibr">104]</ref>.</s><s xml:id="_NFGh7jr">Consequently, the benefits of using CGM in T2DM on intensive insulin therapy are increasingly reflected in guidelines for management of T2DM [54, <ref type="bibr" target="#b58">63,</ref><ref type="bibr">105]</ref> as part of a holistic care plan.</s><s xml:id="_A95PXaJ">Use of premixed insulins may still be recommended to improve adherence with intensive treatment in T2DM.</s><s xml:id="_SGakUNf">Although no prospective studies have examined the use of CGM in people using premixed insulins, the overall benefits and risks of therapy with premixed insulins are comparable with adding a bolus insulin to basal therapy <ref type="bibr">[106]</ref>.</s></p><p xml:id="_twMMc9P"><s xml:id="_jBW7zX6">Less-intensive basal-only insulin therapy is recommended for people with T2DM who are failing on oral therapies <ref type="bibr" target="#b58">[63]</ref>.</s><s xml:id="_FfywZ84">Initiation of basal insulin is associated with episodes of problematic hypoglycemia and is the second most common reason given by people with T2DM for interruption or discontinuation of basal insulin therapy <ref type="bibr">[107,</ref><ref type="bibr">108]</ref>.</s><s xml:id="_tVkfE6F">For people with T2DM on basal insulin therapy, the MOBILE RCT has shown that using CGM can lower HbA1c and reduce both time in hyperglycemia with glucose level greater than 250 mg/dL (13.9 mmol/L) and hypoglycemia event rates over an 8-month period, compared to a control group using SMBG testing alone <ref type="bibr">[19]</ref>.</s><s xml:id="_dG4HvPm">Notably, discontinuing CGM use in this group resulted in the loss of half of the gains in TIR within 6 months of ceasing use <ref type="bibr">[109]</ref>.</s><s xml:id="_sqsAWnf">These data confirm the results of retrospective studies showing a significant reduction in HbA1c for people with T2DM on basal insulin therapy <ref type="bibr" target="#b65">[70,</ref><ref type="bibr">110]</ref>.</s><s xml:id="_7tWKtgy">Together, these outcomes support the proposition that people with T2DM on basal insulin regimens should be provided with access to CGM devices for daily use as is accepted for those on intensive insulin regimens.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KM4CYGG">USING CGM IN CYSTIC FIBROSIS-RELATED DIABETES</head><p xml:id="_wUayNXd"><s xml:id="_pC7CucH">Cystic fibrosis-related diabetes (CFRD) is one of the most common extrapulmonary comorbidities among people with CF, occurring in up to 50% of adults <ref type="bibr">[111]</ref>.</s><s xml:id="_2yMDh5P">CFRD is a form of diabetes caused by relative insulin insufficiency secondary to destruction of pancreatic islets <ref type="bibr">[112,</ref><ref type="bibr">113]</ref>.</s><s xml:id="_STUyfEU">CFRD is associated with worse clinical outcomes, decreased pulmonary function, and higher mortality rates <ref type="bibr">[114]</ref>.</s><s xml:id="_rX9p73b">The reference standard screening for CFRD is annual oral glucose tolerance testing (OGTT), but when CGM has been applied contemporaneously with OGTT testing, CGM has detected CFRD at a higher frequency <ref type="bibr">[115]</ref> and identified glucose abnormalities <ref type="bibr">[116]</ref>.</s><s xml:id="_QKWnZ93">Notably, CGM metrics of hyperglycemia and glycemic variability are superior to HbA1c in differentiating between people with CF who have CFRD and those without <ref type="bibr">[117]</ref>.</s><s xml:id="_FpCtNfu">Furthermore, when compared with SMBG, use of CGM in people with CFRD is associated with improved glycemic control and significantly reduced HbA1c <ref type="bibr">[118]</ref>.</s></p><p xml:id="_X2BScAb"><s xml:id="_7QuuVyU">Given that insulin therapy is an accepted intervention in CFRD, the use of CGM to confirm diagnosis and establish the need for insulin treatment has been proposed <ref type="bibr">[119]</ref>.</s><s xml:id="_KH8suMy">Since up to 96% of school-age children and 85% of adults with CFRD are treated with insulin [120], the application of daily CGM for people with CFRD should be considered in this group.</s><s xml:id="_AxCBvgH">No longitudinal studies have been undertaken to establish whether using CGM in CFRD is associated with improved pulmonary or non-pulmonary outcomes in CF.</s><s xml:id="_5vnUaqM">The role of CGM for women with CFRD during pregnancy is discussed later in this article.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ChacBGc">USE OF CGM IN PEOPLE WITH T2DM NOT ON INSULIN THERAPY</head><p xml:id="_wP6tXbx"><s xml:id="_K6SXSAk">Evidence shows that people with T2DM not on insulin therapy can significantly reduce their HbA1c using CGM devices <ref type="bibr">[21,</ref><ref type="bibr" target="#b16">22,</ref><ref type="bibr">121]</ref>.</s><s xml:id="_kgHTA3E">This reduction is greater for those with a higher HbA1c level at the point of initiation <ref type="bibr">[21]</ref>.</s><s xml:id="_BvhNuXD">Glycemic variability is also reduced in people with T2DM on non-insulin therapy using CGM compared to SMBG <ref type="bibr" target="#b16">[22]</ref>.</s><s xml:id="_CmRhHrF">Similarly, use of CGM amongst people can be associated with reduced acute diabetes events requiring hospital attendance or admission <ref type="bibr" target="#b66">[71]</ref>.</s></p><p xml:id="_3zhFDnn"><s xml:id="_BWzfgZs">In real-world healthcare economies, people with T2DM not on insulin comprise the majority of the diabetes treatment population, and recommending daily access to CGM systems for this group is impractical because of the cost impact.</s><s xml:id="_AbF7aXT">Therefore, the intermittent use of CGM devices can be recommended at regular intervals or during treatment change, as discussed previously.</s><s xml:id="_9G9a2Eu">Therefore, for people with stable T2DM on non-insulin therapies unblinded CGM sensors should be used every 3 months as standard of care.</s><s xml:id="_dSVTRbb">In this way it will be possible to (1) evaluate treatment responses and achievement of goals; (2) adjust therapy as necessary; (3) evaluate risks for microvascular and cardiometabolic complications; and (4) reinforce patient education and diabetes selfmanagement skills (CGM coaching).</s><s xml:id="_f5ZpGfj">This is summarized in Fig. <ref type="figure" target="#fig_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zQwRp9E">IMPORTANCE OF CGM IN T2DM IN THE ELDERLY AND VULNERABLE</head><p xml:id="_95GeGek"><s xml:id="_TKq3Tz2">The incidence of T2DM amongst the elderly population is significant, particularly in highand middle-income countries <ref type="bibr">[122]</ref>.</s><s xml:id="_naCDhGQ">Despite this, there are relatively few studies on the use of CGM in elderly populations and this is an important gap.</s><s xml:id="_HywMZyk">The REPLACE RCT in people with T2DM on intensive insulin therapy found that study participants aged 65 years or older had a 56% reduction in TBR 70 mg/dL, which was comparable to subjects younger than 65 years old <ref type="bibr" target="#b19">[25]</ref>.</s><s xml:id="_eeJaNvJ">A subgroup analysis of the DIAMOND study showed that, in adults aged 60 years or older with T2DM on intensive insulin therapy <ref type="bibr">[20]</ref>, improvements in HbA1c and reduced glycemic variability obtained using daily CGM were not different from those in younger adults.</s><s xml:id="_hedVzr7">Bao and colleagues reported that people with T2DM aged 65 years or older on basal insulin therapy were able to improve TIR and reduce hypoglycemia after starting traditional CGM, at least as significantly as younger adults <ref type="bibr">[123]</ref>.</s><s xml:id="_DHACteH">The outcomes of the RELIEF study on use of isCGM in adults with T2DM aged 65 years or older on intensive insulin therapy have shown that hospital admissions for acute diabetes events were reduced by 34% and 40% in the 12 and 24 months following initiation of isCGM, respectively <ref type="bibr">[124]</ref>.</s></p><p xml:id="_mWBgbuR"><s xml:id="_YFSrKd2">Use of blinded CGM [125] and retrospective insurance claims analysis <ref type="bibr">[126]</ref> have confirmed that hypoglycemia is frequent amongst older populations with T2DM, including those on non-insulin therapy, and those with elevated HbA1c.</s><s xml:id="_SbJqqkn">It is also evident that the risk of severe or fatal hypoglycemia increases considerably in elderly individuals with diabetes who are treated with insulinotropic medications <ref type="bibr">[127]</ref><ref type="bibr">[128]</ref><ref type="bibr">[129]</ref>,</s></p><p xml:id="_99Av2Y9"><s xml:id="_n3XJEJP">and the risk of falls and fractures amongst elderly people with T2DM treated with insulin is increased compared to those only on oral medication <ref type="bibr">[130,</ref><ref type="bibr">131]</ref>.</s><s xml:id="_NQu7DQk">Hypoglycemia in elderly people with T2DM is also associated with increased incidence of cardiovascular events, dementia, and death <ref type="bibr">[131]</ref>.</s><s xml:id="_9Sj82gG">The avoidance of hypoglycemia has therefore been suggested as a greater priority than minimizing HbA1c amongst elderly people with T2DM <ref type="bibr">[132]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_j8DZtcC">The Imperative for De-intensifying Treatment in Elderly People with Diabetes</head><p xml:id="_gvqAkN7"><s xml:id="_bWRk9Nr">The goal of symptom control and maintaining quality of life as people reach advanced age creates a need for treatment de-intensification in a safe manner <ref type="bibr">[133]</ref>.</s><s xml:id="_jNd7mb7">Deprescribing sulfonylurea drugs is a clear target <ref type="bibr">[133,</ref><ref type="bibr">134]</ref>, particularly in elderly people with T2DM with more complications and comorbidities.</s><s xml:id="_S3xcZRM">Clinical management of diabetes in elderly and frail people with diabetes is hampered by the paucity of studies that include this population.</s><s xml:id="_zXnkVC2">It is clear that de-prescribing of medication in elderly people with diabetes required judicious clinical judgement, which can be facilitated with the use of CGM to maintain awareness of glycemic changes.</s><s xml:id="_zeDZ6dg">Since the feasibility and acceptability of CGM in very elderly adults up to 91 years old has also been demonstrated <ref type="bibr">[135]</ref>, the case for wider access and application of CGM in older and elderly people with T2DM is clear (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vzgW75C">Cognitive and Mental Health Concerns in Elderly People with Diabetes</head><p xml:id="_7bNQS5a"><s xml:id="_MEpv7pG">The phenomenon of cognitive decline is associated with aging in the general population <ref type="bibr">[136]</ref>, and risk of developing dementia is increased in T2DM <ref type="bibr">[137]</ref>.</s><s xml:id="_yJRZPv5">The features of cognitive decline can reduce the ability and engagement of elderly people with T2DM to manage their basic self-care tasks <ref type="bibr">[138]</ref>, with the burden of care then transferring to carers and HCPs.</s><s xml:id="_mHZHQs8">Cognitive deficits also contribute to an increased frequency of depression-related symptoms, poorer adherence to treatment, increased risk of hypoglycemia, and ultimately to poorer prognosis <ref type="bibr">[139]</ref>.</s><s xml:id="_s2mppae">In this context, the needs of older adults with T2DM and their caregivers can benefit from the use of CGM in this population.</s><s xml:id="_exjDyaN">Daily use of CGM can help elderly people with T2DM and their carers to manage medication and glycemic risks, with as little extra burden as possible.</s><s xml:id="_kU69gBP">In this way, application of CGM can maintain quality of life for this patient group and limit the risks of functional dependency <ref type="bibr">[140]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rr8RZ7B">CONTROLLING HYPERGLYCEMIA IN ACUTE CARE SETTINGS</head><p xml:id="_geHqdjN"><s xml:id="_ThYHVam">The benefits of using CGM in acute and critical care settings has not been well explored to date, although the impact of glycemic dysregulation for people without diabetes in hospital is becoming better documented.</s><s xml:id="_vEU5tTW">Hyperglycemia in this context is stress induced as a consequence of an inflammatory and adrenergic response, when counterregulatory hormones are released that lead to insulin resistance and reduced insulin secretion.</s><s xml:id="_UUHFjpt">Glucagon release and glycogenolysis can also occur <ref type="bibr">[141,</ref><ref type="bibr">142]</ref>.</s></p><p xml:id="_Q7Dskaw"><s xml:id="_yx4aECZ">Stress-induced hyperglycemia is associated with risk of death or poor outcomes after acute myocardial infarction (AMI) <ref type="bibr">[143]</ref> and intensive control of hyperglycemia in people with diabetes is associated with reduced mortality in the 12 months following an <ref type="bibr">AMI [144]</ref>.</s><s xml:id="_nrETXNx">This effect is most pronounced in people with T2DM naı ¨ve to insulin prior to admission to hospital <ref type="bibr">[144]</ref>, and can persist up to 8 years following intervention <ref type="bibr">[145]</ref>.</s><s xml:id="_qBCwgZA">However, the risks of hypoglycemia following intensive control of hyperglycemia following AMI have also been proposed to confound these beneficial effects of reducing hyperglycemia for people with T2DM following AMI <ref type="bibr">[146,</ref><ref type="bibr">147]</ref>.</s></p><p xml:id="_AJf6XJW"><s xml:id="_wyTvyyC">The association between hyperglycemia and risk of stroke is well established in people with T2DM <ref type="bibr">[148]</ref>.</s><s xml:id="_s3hxrDQ">Poorer outcomes for people suffering acute stroke are even more linked to hyperglycemia <ref type="bibr">[149]</ref>, such that ''stress hyperglycemia'' in patients with stroke and without a diagnosis of diabetes is predictive of a worse prognosis <ref type="bibr">[150]</ref>.</s><s xml:id="_DvM4MBZ">The link between hyperglycemia and stroke is proposed to involve the pro-inflammatory consequences of persistent high glucose <ref type="bibr">[151]</ref> and American Stroke Association guidelines recommend establishing blood glucose levels in the range of 140-180 mg/dL <ref type="bibr">(7.8-10.</ref>0</s><s xml:id="_tP8ZkcZ">mmol/L) as soon as possible following a stroke and to avoid hypoglycemia <ref type="bibr">[152]</ref>.</s></p><p xml:id="_5YRgKg2"><s xml:id="_t5SkrJA">Hyperglycemia is a common and significant adverse consequence of several established cancer therapeutic classes, including immune checkpoint inhibitors (ICIs), phosphatidylinositol 3-kinase (PI3K) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, 5-fluorouracil (5-FU) analogues, and glucocorticoids <ref type="bibr">[153]</ref>.</s><s xml:id="_psy3utM">The mechanism can be related to drug-mediated insulin resistance but not always <ref type="bibr">[153]</ref>.</s><s xml:id="_BHrmtap">This hyperglycemia has been associated with reduced efficacy of cancer therapy <ref type="bibr">[154]</ref>.</s><s xml:id="_e6UPTBe">Use of CGM data has also shown that hyperglycemia associated with in-hospital treatment is also associated with longer hospital stays and worsened prognosis <ref type="bibr">[155,</ref><ref type="bibr">156]</ref>.</s><s xml:id="_N6hGcah">From a clinical perspective, hyperglycemia is established as an independent risk factor for earlier cancer recurrences and higher mortality rates <ref type="bibr">[157]</ref>.</s></p><p xml:id="_pUwswWQ"><s xml:id="_c4a4EdX">As well as the specific conditions discussed above, management of a much wider group of acute surgical patients with comorbid T2DM is also subject to guidance on minimizing hyperglycemia in the hospital setting because of the increased risks for surgical-site infections <ref type="bibr">[158,</ref><ref type="bibr">159]</ref> and increased costs <ref type="bibr">[160]</ref>.</s></p><p xml:id="_ScwGCaV"><s xml:id="_t5ZdTQn">Given the proven role CGM in reducing hyperglycemia with reduced risk of severe hypoglycemia for people with T2DM on intensive therapies <ref type="bibr" target="#b19">[25,</ref><ref type="bibr">161]</ref>, the use of CGM as part of acute management for cardiometabolic, neurological, and oncological conditions must be strongly considered.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VTqywAv">Post-Transplant Hyperglycemia and Diabetes</head><p xml:id="_vnXPPpY"><s xml:id="_NEZGNVZ">Recipients of organ transplants can develop post-transplantation diabetes (PTDM) in the first year after transplantation as a consequence of immunosuppressive therapy and b-cell dysfunction.</s><s xml:id="_YnuYbKk">PTDM is common, affecting up to 30% of kidney <ref type="bibr">[162]</ref>, heart <ref type="bibr">[163]</ref>, liver <ref type="bibr">[164]</ref>, and lung transplant [164] patients who were non-diabetic pre-transplant.</s><s xml:id="_qsyvvNz">Although PTDM is not thought to be associated with microvascular and macrovascular complications, it is associated with increased risk of cardiovascular morbidity and mortality and graft loss, and lower rates of survival in patients with PTDM <ref type="bibr">[165]</ref>.</s></p><p xml:id="_GcAfn3S"><s xml:id="_BMhpMDV">The adverse consequences of PTDM mean that intensive glucose monitoring and management is necessary in the immediate period after transplantation surgery.</s><s xml:id="_VZbDvg9">This can be achieved using CGM, which is straightforward for postsurgical teams to apply and for graft recipients to self-manage during the weeks and months as outpatients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_M6ZgCGJ">Use of CGM in Chronic Kidney Disease (CKD)</head><p xml:id="_3XspMSs"><s xml:id="_kYVEnXS">There is only limited evidence that progression of diabetes-related kidney disease may be slowed using CGM to optimize TIR <ref type="bibr">[166,</ref><ref type="bibr">167]</ref>.</s><s xml:id="_GT3NVPz">However, several studies using CGM have shown that patients with T2DM and stage 3-5 CKD have lower average glucose levels during and immediately after hemodialysis as compared to days not on dialysis <ref type="bibr">[168,</ref><ref type="bibr">169]</ref>.</s><s xml:id="_BDUcXVT">Consequently, it is important to match their basal insulin doses to their glycemic needs during this period, to avoid an increased frequency of hypoglycemia.</s><s xml:id="_2PB3ZGB">In this context, CGM devices can reveal the important daily glycemic patterns for people with T2DM and CKD on hemodialysis and help them manage daily diet and physical activity.</s><s xml:id="_sTs85dz">Another aspect of CKD and other metabolic diseases is that HbA1c can be compromised as a marker of overall glycemia, because it is sensitive to non-glycemic changes in red blood cell volume and turnover, or protein glycation rates.</s><s xml:id="_vyGuECB">Therefore, it has been proposed that the glucose management indicator (GMI) [170], a CGM-derived marker, can be used to evaluate overall glucose exposure for people in whom HbA1c may be an unreliable <ref type="bibr">[171,</ref><ref type="bibr">172]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Hju4yGJ">THE IMPORTANT ROLE OF CGM IN PREGNANCY</head><p xml:id="_f6BxwKu"><s xml:id="_h8u2NqW">Despite advances in antenatal diabetes care, 60% of babies born to women with T1DM are large for gestational age (LGA), which is associated with increased rates of obstetric and neonatal complications <ref type="bibr">[173,</ref><ref type="bibr">174]</ref>.</s><s xml:id="_cMjq9MW">Pregnant women with T2DM have higher than expected rates of perinatal death and increased rates of LGA deliveries <ref type="bibr">[173]</ref>.</s><s xml:id="_89zexmk">For women without diabetes prior to conceiving, GDM <ref type="bibr">[175]</ref> is the dominant condition among pregnancies complicated by diabetes, affecting 3-10% of all pregnancies and is associated with risk of fetal macrosomia, shoulder dystocia, birth trauma, and caesarean section <ref type="bibr">[175]</ref>.</s><s xml:id="_sm9UAyD">It is important to note that GDM is a metabolic disorder distinct from pregestational diabetes.</s><s xml:id="_9NBCrAq">It is less severe and typically resolves after giving birth.</s><s xml:id="_fXGw9km">The benefits of using CGM in GDM need to be better researched.</s><s xml:id="_XeUTz6X">However, data obtained using CGM in women with GDM show that significant daytime glucose variability and elevated mean glucose levels overnight are associated with increased risk of fetal complications, including LGA, in GDM <ref type="bibr">[176]</ref><ref type="bibr">[177]</ref><ref type="bibr">[178]</ref>.</s><s xml:id="_4hYq5QK">The high rate of fetal growth after the 30th week of gestation forces the rapid implementation of effective therapy for GDM, which is usually diagnosed around the 26th to 28th week of gestation.</s></p><p xml:id="_chg8D8X"><s xml:id="_5c65Z7D">Meta-analyses of studies investigating the impact of CGM on GDM pregnancies have concluded that women with GDM better implemented dietary recommendations and achieved better glycemic control when using CGM, compared to women using SMBG alone <ref type="bibr">[179,</ref><ref type="bibr">180]</ref>.</s><s xml:id="_ndjS5Ux">The incidence of LGA births was also reduced for women with GDM who used CGM, compared to those using SMBG <ref type="bibr">[179,</ref><ref type="bibr">180]</ref>.</s><s xml:id="_Mf8uJ4y">Amongst all pregnancies affected by diabetes, LGA infants are predisposed to developing obesity, T2DM, and cardiovascular disease, persisting into adulthood <ref type="bibr">[181,</ref><ref type="bibr">182]</ref>.</s><s xml:id="_QEYQhAu">As therapies for CF are offering greater health and longevity, women with CF are increasingly pursuing pregnancy <ref type="bibr">[183]</ref>.</s><s xml:id="_muAA73s">The prevalence of GDM or CFRD in this group is high, with up to 66% of pregnancies affected <ref type="bibr">[184]</ref> and with associated risks for LGA and perinatal complications <ref type="bibr">[183]</ref>.</s></p><p xml:id="_W7qq6Sg"><s xml:id="_f5qnAvq">Application of CGM during pregnancy has shown that during the critical stages of early pregnancy women with pregestational T1DM or T2DM spend only 50% of each day (12 h) with glucose levels in the target glucose range 70-140 mg/dL <ref type="bibr">(3.9-7.8 mmol/L) [185]</ref>.</s><s xml:id="_Ce4mpgJ">The <ref type="bibr">CONCEPTT trial [186]</ref> in 215 pregnant women with T1DM, using a target glucose range of 63-140 mg/dL <ref type="bibr">(3.5-7.8</ref> mmol/L), showed that TIR increased by approximately 10% (2 h 24 min/day) from the first to the third trimester.</s><s xml:id="_6DUzdbN">The CONCEPTT trial also showed that use of CGM helps women with T1DM improve their %TIR during pregnancy compared to controls using SMBG (68% vs 61%; 16 h 19 min vs 14 h 38 min/day) <ref type="bibr">[186]</ref>.</s><s xml:id="_Xmkk8tS">This improvement in glycemia was achieved without increased maternal hypoglycemia.</s></p><p xml:id="_CU9kFSV"><s xml:id="_2b9hAwY">A retrospective analysis <ref type="bibr">[187]</ref> of CGM data from both the CONCEPTT trial <ref type="bibr">[186]</ref> and a Swedish retrospective study <ref type="bibr">[188]</ref> on a total of 386 pregnancies found that women with T1DM who went on to have LGA deliveries had significantly lower time in the pregnancy target glucose range from around 6 to 8 weeks of gestation, compared to women with T1DM who delivered normal sized infants.</s><s xml:id="_VwWHSkt">Ultimately, normal birth weight for women with T1DM is associated with achieving significantly lower mean daily glucose concentration and higher time in target glucose range from before the end of the first trimester <ref type="bibr">[187]</ref>.</s><s xml:id="_yrFBYvA">The relevance of CGM in this context is further underscored by data indicating increased glucose variability is an independent risk factor for delivering LGA infants for women with pregestational diabetes <ref type="bibr">[189,</ref><ref type="bibr">190]</ref>, and that use of isCGM is associated with a lower rate of spontaneous abortion in pregnant women with T1DM, when compared to SMBG <ref type="bibr">[191]</ref>.</s></p><p xml:id="_BaB59GR"><s xml:id="_9WjXSBJ">The outcome of these studies in T1DM has led to international consensus guidelines which propose that pregnant women with pregestational diabetes or gestational diabetes spend greater than 70% of time with glucose between 63 and 140 mg/dL <ref type="bibr">(3.5-7.8</ref> mmol/L) <ref type="bibr" target="#b25">[30]</ref>.</s></p><p xml:id="_QHmp6e2"><s xml:id="_4mf6M2t">Specific studies on using CGM or isCGM in pregnancy in T2DM and in GDM are planned to complete this picture <ref type="bibr">[192]</ref>.</s><s xml:id="_MkVNAAc">Overall, the need to meet CGM-derived glucose targets for maternal glycemia from early pregnancy [187] emphasizes the need to use CGM devices in women either with pregestational diabetes or GDM, including in women with CFRD, from the earliest possible moment in pregnancy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QAqKYxf">MODERN MANAGEMENT OF DIABETES WITH CGM: A CHALLENGE FOR HEALTHCARE PROFESSIONALS AND HEALTHCARE SERVICES</head><p xml:id="_8td7PgZ"><s xml:id="_zNwcBvj">Expanding the application of CGM systems for management of people with T2DM and beyond will require a considerable adjustment in diabetes service delivery.</s><s xml:id="_2y8RhYZ">Key among these is education for HCPs, particularly in understanding the heterogeneity of T2DM and the diverse patient profiles that must be managed <ref type="bibr" target="#b80">[85,</ref><ref type="bibr" target="#b81">86]</ref>.</s><s xml:id="_56Tud8C">Similarly, the high value of CGM in a much larger population of users is due to its utility for remote monitoring, reducing the need for in-clinic consultations and for streamlining workflows <ref type="bibr">[193]</ref>.</s><s xml:id="_cTbJZVf">A concern in this context is a 2018 survey of primary care physicians across the EU, which found that 89% did not engage with telemedicine solutions with their patients, that 81% did not use it with other HCPs, and that 51% were either unaware that telemedicine education was available or did not access it <ref type="bibr">[194]</ref>.</s><s xml:id="_ptjKRtS">This landscape is likely to have changed as a consequence of the COVID-19 pandemic, during which telemedicine became the predominant mode of diabetes consultations <ref type="bibr">[195]</ref>.</s><s xml:id="_DTtsrjK">Although limited, the available evidence suggests that telemedicine is not inferior to face-to-face visits in diabetes care <ref type="bibr">[195,</ref><ref type="bibr">196]</ref>, and that primary care teams and patients have embraced it <ref type="bibr">[197,</ref><ref type="bibr">198]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8TU9eZU">THE EXPANDING FRONTIER OF MODERN DIABETES CARE: A MAP OF UNEXPLORED OPPORTUNITY</head><p xml:id="_YHN4jVe"><s xml:id="_JHzWu5f">We have reviewed the evidence base for use of CGM in people with diabetes and also non-diabetic individuals who are challenged by hyperglycemia in acute circumstances.</s><s xml:id="_KuRkQgN">This has allowed us to propose the map of applications outlined in Fig. <ref type="figure" target="#fig_1">2</ref>. The number of potential applications for using CGM for managing glucose dysregulation is far greater than those agreed in consensus guidelines and for which reimbursement is typically provided by national health services.</s><s xml:id="_hHdygfE">Seizing this opportunity will require the concerted efforts of HCPs and professional societies, to create and agree the necessary guidelines for the indications and frequency of use of CGM in the diverse conditions described.</s><s xml:id="_8ayDXEj">Equally, there is a significant unmet need for evidence that the proposed use of CGM can be associated with improved outcomes in each case.</s><s xml:id="_PevEHPY">This evidence will be the foundation on which budget stakeholders will assess the cost-benefit for expanding use of CGM and recommend access.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GYFUwjX">CONCLUSIONS</head><p xml:id="_Kkkg7DA"><s xml:id="_tJnKqVX">The evidence on which to recommend inclusion of CGM technology as the standard of care for all people with T1DM and T2DM is available, including for people with T2DM on noninsulin therapies.</s><s xml:id="_3h6wgru">Many other clinical scenarios are also deserving of the application of CGM in order to manage acute episodes of glycemic dysregulation in people without established diabetes.</s><s xml:id="_WHuJ2We">The value of CGM as an intermittent intervention at predefined points in the patient journey is key to its widespread and cost-effective use.</s><s xml:id="_3ckJZ6U">Extracting the untapped value of CGM technologies in diabetes care is a significant challenge for healthcare teams and healthcare economies, and will require a paradigm shift in attitudes, education, and service design.</s><s xml:id="_XGwkgR3">disease, PTDM post-transplant diabetes, T1DM type 2 diabetes, T2DM type 2 diabetes</s></p><p xml:id="_gDDq8J3"><s xml:id="_C3T9Kkk">Authorship.</s><s xml:id="_UPKtDbF">All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.</s></p><p xml:id="_3TA62jj"><s xml:id="_caTFzN2">Medical Writing and Editorial Assistance.</s><s xml:id="_ExVvnvY">Editorial assistance in the preparation of this manuscript was provided by Dr Robert Brines of Bite Medical Consulting.</s><s xml:id="_zX5eStn">Funding for writing support was provided by Abbott Diabetes Care.</s></p><p xml:id="_4WGbSXe"><s xml:id="_HppRMgM">Author Contributions.</s><s xml:id="_rh2jcTr">Tomasz Klupa, Leszek Czupryniak, Grzegorz Dzida, Piotr Fichna, Przemyslawa Jarosz-Chobot, Janusz Gumprecht, Malgorzata Mysliwiec, Agnieszka Szadkowska, Dorota Bomba-Opon, Krzysztof Czajkowski, Maciej T. Malecki and Dorota Zozulinska-Ziolkiewicz discussed the topics contained in this manuscript over two expert advisory panels.</s><s xml:id="_QGyEfFM">All authors contributed to the concept and design of the manuscript and worked collaboratively to review and prepare the final manuscript.</s></p><p xml:id="_zJGfJQ8"><s xml:id="_EcSqtR3">Disclosures.</s><s xml:id="_YcHp7U3">Tomasz Klupa has received honoraria from Abbott, Ascencia, Medtronic, Roche, and research support from Medtronic.</s><s xml:id="_v7SwDZh">Leszek Czupryniak has received honoraria from Abbott, Abbott, Ascencia, Medtronic, Roche.</s><s xml:id="_2rg94MR">Grzegorz Dzida has received honoraria from Abbott, Roche.</s><s xml:id="_AMcf3Q8">Piotr Fichna has received honoraria from Abbott.</s><s xml:id="_DPzSV52">Przemyslawa Jarosz-Chobot has received honoraria from Abbott, Ascencia, Dexcom, Medtronic, Roche.</s><s xml:id="_BzGTjAE">Janusz Gumprecht has received honoraria from Abbott, Ascencia.</s><s xml:id="_gvXYGkR">Malgorzata Mysliwiec has received honoraria from Abbott, Ascencia, Dexcom, Medtronic.</s><s xml:id="_anVmfQ8">Agnieszka Szadkowska has received honoraria from Abbott, Ascencia, Dexcom, Medtronic.</s><s xml:id="_fAGjE76">Dorota Bomba-Opon has received honoraria from Abbott.</s><s xml:id="_NhksHyD">Krzysztof Czajkowski has received honoraria from Abbott.</s><s xml:id="_7KKu9pY">Maciej T. Malecki has received honoraria from Abbott, Ascensia, Dexcom, Medtronic, Roche.</s><s xml:id="_smFmdy4">Dorota Zozulinska-Ziolkiewicz has received honoraria from Abbott, Ascensia, Dexcom, Medtronic, Roche.</s></p><p xml:id="_NuxAvCJ"><s xml:id="_WCAXUgh">Compliance with Ethics Guidelines.</s><s xml:id="_mJCwazX">This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.</s><s xml:id="_MFbtWRx">All statements and recommendations comply with the 1964 Declaration of Helsinki.</s></p><p xml:id="_Gjyh4Yq"><s xml:id="_m89wHAr">Open Access.</s><s xml:id="_3mFgyqG">This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.</s><s xml:id="_FUg4M2Y">The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.</s><s xml:id="_ZJSV2hw">If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_3VXrYqG">To view a copy of this licence, visit <ref type="url" target="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by- nc/4.0/</ref>.</s><s xml:id="_n7rSJSp">17.</s><s xml:id="_3KmMCZE"><ref type="bibr">Battelino T, Conget I, Olsen B, et</ref> al.</s><s xml:id="_YBn3UDZ">The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.</s><s xml:id="_5wxBHaf">Diabetologia.</s><s xml:id="_dMCqnkH">2012;55: 3155-62.</s><s xml:id="_dKtveNF"><ref type="url" target="https://doi.org/10.1007/s00125-012-2708-9">https://doi.org/10.1007/s00125-012-2708- 9</ref>. 18. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.</s><s xml:id="_c5GejEn">Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial.</s><s xml:id="_3Zv8b58">Diabetes Care.</s><s xml:id="_kT5h8uC">2010;33: 17-22.</s><s xml:id="_ZK5ZT4E"><ref type="url" target="https://doi.org/10.2337/dc09-1502">https://doi.org/10.2337/dc09-1502</ref>.</s><s xml:id="_Ak7kYdm">19.</s><s xml:id="_JGxf5XC">Martens T, Beck RW, Bailey R, et al.</s><s xml:id="_pKmfh6p">Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin.</s><s xml:id="_hJc9cdH">JAMA.</s><s xml:id="_q8wdd65">2021;325:2262-72.</s><s xml:id="_5u7E4T8"><ref type="url" target="https://doi.org/10.1001/jama.2021.7444">https://doi.org/  10.1001/jama.2021.7444</ref>.</s><s xml:id="_bfmxCef">20.</s><s xml:id="_z5v4aJm">Beck RW, Riddlesworth TD, Ruedy K, et al.</s><s xml:id="_d5CC7qC">Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections.</s><s xml:id="_jT6fW45">Ann Intern Med.</s><s xml:id="_ZncxQXJ">2017;167: 365.</s><s xml:id="_EVhhaJQ"><ref type="url" target="https://doi.org/10.7326/m16-2855">https://doi.org/10.7326/m16-2855</ref>.</s><s xml:id="_WwFNmMK">21.</s><s xml:id="_PnfFWG2">Wright EE, Kerr MSD, Reyes IJ, Nabutovsky Y, Miller E. Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_EdbgjjY"><s xml:id="_vgwrHvF">Fig. 1 Intermittent use of CGM in the management of stable disease in T2DM.</s><s xml:id="_tcsr3We">CGM continuous glucose monitoring, T2DM type 2 diabetes</s></p></div></figDesc><graphic coords="10,74.27,77.56,215.72,209.99" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p xml:id="_uSa8hp2"><s xml:id="_Nye7WSs">Fig. 2 Intermittent use of CGM in the management of heterogeneous aspects of T2DM and hyperglycemia.</s><s xml:id="_YndNh9T">CGM continuous glucose monitoring, CKD chronic kidney</s></p></div></figDesc><graphic coords="14,79.03,77.56,451.65,258.75" type="bitmap" /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_VttByYp"><s xml:id="_up3KSD6">Diabetes Ther (2023)14:1241-1266</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_GXJACkf">ACKNOWLEDGEMENTS</head><p xml:id="_tzTnSCZ"><s xml:id="_9cnr4Hu">Funding.</s><s xml:id="_qGmQk9V">The Rapid Service Fee was vided by <rs type="funder">Abbott Diabetes Care</rs>, who also provided support for the medical writer.</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_hrHn3ks">Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices</title>
		<author>
			<persName><forename type="first">G</forename><surname>Freckmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pleus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Setford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296818812062</idno>
		<ptr target="https://doi.org/10.1177/1932296818812062" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_yXsmVmx">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="575" to="583" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Freckmann G, Pleus S, Grady M, Setford S, Levy B. Measures of accuracy for continuous glucose mon- itoring and blood glucose monitoring devices. J Diabetes Sci Technol. 2019;13:575-83. https://doi. org/10.1177/1932296818812062.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_zC8XYtd">The performance and usability of a factory-calibrated flash glucose monitoring system</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Bode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Klaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alva</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1089/dia.2014.0378</idno>
		<ptr target="https://doi.org/10.1089/dia.2014.0378" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5eM9mz9">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="787" to="794" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-cali- brated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787-94. https://doi.org/10. 1089/dia.2014.0378.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_TW67N2U">of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Ajjan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jennings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leelarathna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rayman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Wilmot</surname></persName>
		</author>
		<idno type="DOI">10.1177/1479164118756240</idno>
		<ptr target="https://doi.org/10.1177/1479164118756240" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_A3Mpm7F">Diabetes Vasc Dis Re</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="175" to="184" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ajjan RA, Cummings MH, Jennings P, Leelarathna L, Rayman G, Wilmot EG. of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice. Diabetes Vasc Dis Re. 2018;15:175-84. https://doi. org/10.1177/1479164118756240.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_bGB5ZKp">A new era in continuous glucose monitoring: food and drug administration creates a new category of factory-calibrated nonadjunctive, interoperable class II medical devices</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Akturk</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2018.0142</idno>
		<ptr target="https://doi.org/10.1089/dia.2018.0142" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_A6VTtjn">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="391" to="394" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garg SK, Akturk HK. A new era in continuous glu- cose monitoring: food and drug administration creates a new category of factory-calibrated nonad- junctive, interoperable class II medical devices. Diabetes Technol Ther. 2018;20:391-4. https://doi. org/10.1089/dia.2018.0142.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_XY2eT89">Landscape of continuous glucose monitoring (CGM) and integrated CGM: accuracy considerations</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alva</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0236</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0236" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2VXpSfX">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="5" to="11" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bailey TS, Alva S. Landscape of continuous glucose monitoring (CGM) and integrated CGM: accuracy considerations. Diabetes Technol Ther. 2021;23: 5-11. https://doi.org/10.1089/dia.2021.0236.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_Mhgchf9">Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Alva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brazg</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296820958754</idno>
		<ptr target="https://doi.org/10.1177/1932296820958754" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_G4zmQ5s">J Diabetes Sci Technol</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Alva S, Bailey T, Brazg R, et al. Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol. 2020. https://doi.org/10.1177/ 1932296820958754.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_NxC9vTq">Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Joseph</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296820911919</idno>
		<ptr target="https://doi.org/10.1177/1932296820911919" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_WxBjwvV">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="167" to="173" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Joseph JI. Review of the long-term implantable senseonics continuous glucose moni- toring system and other continuous glucose moni- toring systems. J Diabetes Sci Technol. 2021;15: 167-73. https://doi.org/10.1177/ 1932296820911919.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_PYuK65T">Performance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">N</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Laffel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Wadwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Garg</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2018.0143</idno>
		<ptr target="https://doi.org/10.1089/dia.2018.0143" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NXvxfhR">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="428" to="433" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shah VN, Laffel LM, Wadwa RP, Garg SK. Perfor- mance of a factory-calibrated real-time continuous glucose monitoring system utilizing an automated sensor applicator. Diabetes Technol Ther. 2018;20: 428-33. https://doi.org/10.1089/dia.2018.0143.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_7gn27pY">Sustainable use of a real-time continuous glucose monitoring system from 2018 to 2020</title>
		<author>
			<persName><forename type="first">J</forename><surname>Van Der Linden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Walker</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0014</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0014" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_J6GdzsR">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="508" to="511" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van der Linden J, Welsh JB, Walker TC. Sustainable use of a real-time continuous glucose monitoring system from 2018 to 2020. Diabetes Technol Ther. 2021;23:508-11. https://doi.org/10.1089/dia.2021. 0014.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_AwSFPDs">Clinical efficacy of professional continuous glucose monitoring in improving glycemic control among children with type 1 diabetes mellitus: an open-label randomized control trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Raviteja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dayal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sachdeva</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-019-42555-6</idno>
		<ptr target="https://doi.org/10.1038/s41598-019-42555-6" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_MwPvKt5">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">6120</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raviteja KV, Kumar R, Dayal D, Sachdeva N. Clinical efficacy of professional continuous glucose moni- toring in improving glycemic control among chil- dren with type 1 diabetes mellitus: an open-label randomized control trial. Sci Rep. 2019;9:6120. https://doi.org/10.1038/s41598-019-42555-6.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_qJUM7kZ">Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Polonsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Hirsch</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2016.19976</idno>
		<ptr target="https://doi.org/10.1001/jama.2016.19976" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_N23HKm6">JAMA</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="379" to="387" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317: 379-87. https://doi.org/10.1001/jama.2016.19976.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_B5DuZgs">REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Aleppo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Ruedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Riddlesworth</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc16-2482</idno>
		<ptr target="https://doi.org/10.2337/dc16-2482" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5DVSmdK">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="538" to="545" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing con- tinuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017;40:538-45. https://doi.org/10.2337/dc16- 2482.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_pBtzJ36">Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Riddlesworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ruedy</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2016.19975</idno>
		<ptr target="https://doi.org/10.1001/jama.2016.19975" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_XvfwU49">JAMA</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="page" from="371" to="378" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic con- trol in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371-8. https://doi.org/10.1001/ jama.2016.19975.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_GsdjdWq">Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Petruz ˇelkova ´l</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grunberger</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc19-0888</idno>
		<ptr target="https://doi.org/10.2337/dc19-0888" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jBgwSEz">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="37" to="43" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">S ˇoupal J, Petruz ˇelkova ´L, Grunberger G, et al. Gly- cemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2019;43:37-43. https://doi.org/10.2337/dc19-0888.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_VB2VNKn">Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Biester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kordonouri</surname></persName>
		</author>
		<idno type="DOI">10.1111/pedi.12735</idno>
		<ptr target="https://doi.org/10.1111/pedi.12735" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Mhf6TJ8">Pediatr Diabetes</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1294" to="1301" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19:1294-301. https://doi. org/10.1111/pedi.12735.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_YnMd7qe">Intermittently scanned continuous glucose monitoring for type 1 diabetes</title>
		<author>
			<persName><forename type="first">L</forename><surname>Leelarathna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Neupane</surname></persName>
		</author>
		<idno type="DOI">10.2337/ds20-0069</idno>
		<ptr target="https://doi.org/10.2337/ds20-0069" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ujVqhEf">Diabetes Spectr</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="184" to="189" />
			<date type="published" when="2021">2022. 2021</date>
		</imprint>
	</monogr>
	<note>New Engl J Med</note>
	<note type="raw_reference">Leelarathna L, Evans ML, Neupane S, et al. Inter- mittently scanned continuous glucose monitoring for type 1 diabetes. New Engl J Med. 2022. https:// doi.org/10.1056/nejmoa2205650. noninsulin therapy. Diabetes Spectr. 2021;34: 184-9. https://doi.org/10.2337/ds20-0069.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_ysX7Mv9">Flash glucose monitoring helps achieve glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Onoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjdrc-2019-001115</idno>
		<ptr target="https://doi.org/10.1136/bmjdrc-2019-001115" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2zPmtUh">BMJ Open Diabetes Res Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">1115</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a random- ized controlled trial. BMJ Open Diabetes Res Care. 2020;8:e001115. https://doi.org/10.1136/bmjdrc- 2019-001115.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_yhm4CZQ">Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections</title>
		<author>
			<persName><forename type="first">T</forename><surname>Riddlesworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-017-0281-4</idno>
		<ptr target="https://doi.org/10.1007/s13300-017-0281-4" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_F8drnuT">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="947" to="951" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injec- tions. Diabetes Ther. 2017;8:947-51. https://doi. org/10.1007/s13300-017-0281-4.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_HzeE37A">Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bolinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Antuna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Geelhoed-Duijvestijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kro ¨ger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weitgasser</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(16)31535-5</idno>
		<ptr target="https://doi.org/10.1016/s0140-6736(16)31535-5" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_4GtbCyK">Lancet</title>
		<imprint>
			<biblScope unit="volume">388</biblScope>
			<biblScope unit="page" from="2254" to="2263" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kro ¨- ger J, Weitgasser R. Novel glucose-sensing technol- ogy and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254-63. https://doi.org/10. 1016/s0140-6736(16)31535-5.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_bgkWRvb">Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter open-label randomized controlled trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Haak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hanaire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ajjan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hermanns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Riveline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rayman</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-016-0223-6</idno>
		<ptr target="https://doi.org/10.1007/s13300-016-0223-6" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_YApVB8H">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="55" to="73" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. https://doi.org/10. 1007/s13300-016-0223-6.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_Qz8fkcS">Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Champakanath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Akturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Alonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Snell-Bergeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">N</forename><surname>Shah</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc21-2004</idno>
		<ptr target="https://doi.org/10.2337/dc21-2004" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TVB4XsJ">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="750" to="753" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Champakanath A, Akturk HK, Alonso GT, Snell- Bergeon JK, Shah VN. Continuous glucose moni- toring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care. 2022;45:750-3. https://doi.org/10.2337/dc21-2004.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_4VCE7yZ">Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seibold</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-022-01253-9</idno>
		<ptr target="https://doi.org/10.1007/s13300-022-01253-9" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_GxFRdVc">Diabetes Ther</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022. https:// doi.org/10.1007/s13300-022-01253-9.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title level="m" type="main" xml:id="_ars2dqg">Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association</title>
		<author>
			<persName><forename type="first">G</forename><surname>Agiostratidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Anhalt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ball</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc17-1624</idno>
		<imprint>
			<publisher>JDRF International</publisher>
			<pubPlace>The</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Agiostratidou G, Anhalt H, Ball D, et al. Standard- izing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Dia- betes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_eARVKcf">Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange</title>
		<author>
			<persName><forename type="first">M</forename><surname>Leona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Harry</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc17-1624</idno>
		<ptr target="https://doi.org/10.2337/dc17-1624" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Dcddtc2">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1622" to="1630" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017;40:1622-30. https:// doi.org/10.2337/dc17-1624.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_GG2Ay5h">International consensus on use of continuous glucose monitoring</title>
		<author>
			<persName><forename type="first">T</forename><surname>Danne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nimri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Battelino</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc17-1600</idno>
		<ptr target="https://doi.org/10.2337/dc17-1600" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_pwPS9JE">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1631" to="1640" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitor- ing. Diabetes Care. 2017;40:1631-40. https://doi. org/10.2337/dc17-1600.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_aaDWqxK">Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range</title>
		<author>
			<persName><forename type="first">T</forename><surname>Battelino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Danne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<idno type="DOI">10.2337/dci19-0028</idno>
		<ptr target="https://doi.org/10.2337/dci19-0028" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_XafmCCv">Diabetes Care</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the inter- national consensus on time in range. Diabetes Care. 2019. https://doi.org/10.2337/dci19-0028.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_GeFSCKE">Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0374</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0374" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NrRP9cv">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="153" to="156" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beck RW, Bergenstal RM. Continuous glucose monitoring for type 2 diabetes: how does it com- pare with type 1 diabetes? Diabetes Technol Ther. 2022;24:153-6. https://doi.org/10.1089/dia.2021. 0374.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_WjjmnVn">Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Strock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">X</forename><surname>Xi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jdiacomp.2021.108106</idno>
		<ptr target="https://doi.org/10.1016/j.jdiacomp.2021.108106" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jJeaxNY">J Diabetes Complicat</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">108106</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bergenstal RM, Mullen DM, Strock E, Johnson ML, Xi MX. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. J Diabetes Complicat. 2022;36: 108106. https://doi.org/10.1016/j.jdiacomp.2021. 108106.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_NEdbnKa">Flash glucose monitoring and patient satisfaction: a meta-review of systematic reviews</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dı ´ez-Ferna ´ndez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Rodrı ´guez-Huerta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Miro ´n-Gonza ´lez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Laredo-Aguilera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Martı ´n-Espinosa</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph18063123</idno>
		<ptr target="https://doi.org/10.3390/ijerph18063123" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_nptHpU8">Int J Environ Res Pu</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">3123</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dı ´ez-Ferna ´ndez A, Rodrı ´guez-Huerta MD, Miro ´n- Gonza ´lez R, Laredo-Aguilera JA, Martı ´n-Espinosa NM. Flash glucose monitoring and patient satisfac- tion: a meta-review of systematic reviews. Int J Environ Res Pu. 2021;18:3123. https://doi.org/10. 3390/ijerph18063123.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_rn56tAZ">Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the landmark study</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Noar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Blalock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Polonsky</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2020.0666</idno>
		<ptr target="https://doi.org/10.1089/dia.2020.0666" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qbQVAKf">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="35" to="39" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilbert TR, Noar A, Blalock O, Polonsky WH. Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the land- mark study. Diabetes Technol Ther. 2021;23:35-9. https://doi.org/10.1089/dia.2020.0666.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_RkEfa6W">The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the diamond randomized clinical trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Polonsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Ruedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc17-0133</idno>
		<ptr target="https://doi.org/10.2337/dc17-0133" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_mGcZtgc">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">170</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Polonsky WH, Hessler D, Ruedy KJ, Beck RW. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 dia- betes: further findings from the diamond random- ized clinical trial. Diabetes Care. 2017;40:170. https://doi.org/10.2337/dc17-0133.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_YG2tjkB">Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a realworld study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Charleer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathieu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nobels</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2017-02498</idno>
		<ptr target="https://doi.org/10.1210/jc.2017-02498" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_bvHQAAX">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="1224" to="1232" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Charleer S, Mathieu C, Nobels F, et al. Effect of continuous glucose monitoring on glycemic con- trol, acute admissions, and quality of life: a real- world study. J Clin Endocrinol Metab. 2018;103: 1224-32. https://doi.org/10.1210/jc.2017-02498.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_ymqkqVr">Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational realworld cohort study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Charleer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Block</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Huffel</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc19-1610</idno>
		<ptr target="https://doi.org/10.2337/dc19-1610" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_vR3YwkC">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="389" to="397" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Charleer S, Block CD, Huffel LV, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continu- ous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real- world cohort study. Diabetes Care. 2020;43:389-97. https://doi.org/10.2337/dc19-1610.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_uf9ya6X">Important drop rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Roussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename><surname>Riveline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vicaut</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc20-1690</idno>
		<ptr target="https://doi.org/10.2337/dc20-1690" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_UqtddAd">Diabetes Care</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roussel R, Riveline J-P, Vicaut E, et al. Important drop rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021. https://doi.org/10.2337/ dc20-1690.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_KMrBEBV">Reduced rate of acute diabetes events with flash glucose monitoring is sustained for two-years after initiation: extended from the RELIEF study</title>
		<author>
			<persName><forename type="first">J-P</forename><surname>Riveline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vicaut</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2022.0085</idno>
		<ptr target="https://doi.org/10.1089/dia.2022.0085" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_J54WJ7P">Diabetes Technol Ther</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Riveline J-P, Roussel R, Vicaut E, et al. Reduced rate of acute diabetes events with flash glucose moni- toring is sustained for two-years after initiation: extended from the RELIEF study. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia. 2022.0085.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_QRyRAqH">Important decrease in hospitalizations for acute diabetes events following FreeStyle LibreÒ system initiation in people with type 2 diabetes on basal insulin therapy in France</title>
		<author>
			<persName><forename type="first">B</forename><surname>Guerci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Levrat-Guillen</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2022.0271</idno>
		<ptr target="https://doi.org/10.1089/dia.2022.0271" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_z9qejj2">Diabetes Technol Ther</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guerci B, Roussel R, Levrat-Guillen F, et al. Impor- tant decrease in hospitalizations for acute diabetes events following FreeStyle LibreÒ system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia.2022.0271.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_NUbvA2x">Impact of type 1 diabetes technology on family members/ significant others of people with diabetes</title>
		<author>
			<persName><forename type="first">K</forename><surname>Barnard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Crabtree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Adolfsson</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296816645365</idno>
		<ptr target="https://doi.org/10.1177/1932296816645365" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_njXQW8d">Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="824" to="830" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barnard K, Crabtree V, Adolfsson P, et al. Impact of type 1 diabetes technology on family members/ significant others of people with diabetes. Diabetes Sci Technol. 2016;10:824-30. https://doi.org/10. 1177/1932296816645365.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_pPqDQyd">Flash glucose monitoring in young people with type 1 diabetesa qualitative study of young people, parents and health professionals: &apos;it makes life much easier</title>
		<author>
			<persName><forename type="first">L</forename><surname>Beasant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thomas</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2022-070477</idno>
		<ptr target="https://doi.org/10.1136/bmjopen-2022-070477" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_JzJXcvp">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">70477</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beasant L, Cullen F, Thomas E, et al. Flash glucose monitoring in young people with type 1 diabetes- a qualitative study of young people, parents and health professionals: &apos;it makes life much easier.&apos; BMJ Open. 2023;13:e070477. https://doi.org/10. 1136/bmjopen-2022-070477.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_EUJfkFr">Exploring parental perspectives after commencement of flash glucose monitoring for type 1 diabetes in adolescents and young adults not meeting glycaemic targets: a qualitative study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Aum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Crocket</surname></persName>
		</author>
		<idno type="DOI">10.1111/dme.14188</idno>
		<ptr target="https://doi.org/10.1111/dme.14188" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_23TWnPk">Diabet Med</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="657" to="664" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Boucher SE, Aum SH, Crocket HR, et al. Exploring parental perspectives after commencement of flash glucose monitoring for type 1 diabetes in adoles- cents and young adults not meeting glycaemic tar- gets: a qualitative study. Diabet Med. 2020;37: 657-64. https://doi.org/10.1111/dme.14188.</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_TaXuuFe">Continuous glucose monitoring in children with type 1 diabetes improves well-being, alleviates worry and fear of hypoglycemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Clemente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pintus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Soni</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2018.0347</idno>
		<ptr target="https://doi.org/10.1089/dia.2018.0347" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_C9qGRnz">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="133" to="137" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ng SM, Moore HS, Clemente MF, Pintus D, Soni A. Continuous glucose monitoring in children with type 1 diabetes improves well-being, alleviates worry and fear of hypoglycemia. Diabetes Technol Ther. 2019;21:133-7. https://doi.org/10.1089/dia. 2018.0347.</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_zF45UrW">Paediatric society and hyperinsulinism charity national surveys on CGM access for patients with recurrent hypoglycaemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dearman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mushtaq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Randell</surname></persName>
		</author>
		<idno type="DOI">10.1210/jendso/bvad021</idno>
		<ptr target="https://doi.org/10.1210/jendso/bvad021" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_rThVucQ">J Endocr Soc</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ng SM, Dearman S, Fisher M, Mushtaq T, Randell T. Paediatric society and hyperinsulinism charity national surveys on CGM access for patients with recurrent hypoglycaemia. J Endocr Soc. 2023;7:21. https://doi.org/10.1210/jendso/bvad021.</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_kC4bhHq">Continuous glucose monitoring in older people with diabetes and memory problems: a mixed-methods feasibility study in the UK</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mattishent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salter</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2019-032037</idno>
		<ptr target="https://doi.org/10.1136/bmjopen-2019-032037" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_zHHqyGs">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">32037</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mattishent K, Lane K, Salter C, et al. Continuous glucose monitoring in older people with diabetes and memory problems: a mixed-methods feasibility study in the UK. BMJ Open. 2019;9:e032037. https://doi.org/10.1136/bmjopen-2019-032037.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_6N5DGzR">Continuous glucose monitoring data sharing in older adults with type 1 diabetes: pilot intervention study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Litchman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chamberlain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Grigorian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Iacob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Berg</surname></persName>
		</author>
		<idno type="DOI">10.2196/35687</idno>
		<ptr target="https://doi.org/10.2196/35687" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_zdPjjCj">JMIR Diabetes</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">35687</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Allen NA, Litchman ML, Chamberlain J, Grigorian EG, Iacob E, Berg CA. Continuous glucose moni- toring data sharing in older adults with type 1 dia- betes: pilot intervention study. JMIR Diabetes. 2022;7:e35687. https://doi.org/10.2196/35687.</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_YTKJD8y">Impact of real-time CGM data sharing on quality of life in the caregivers of adults and children with type 1 diabetes</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Polonsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Fortmann</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296820978423</idno>
		<ptr target="https://doi.org/10.1177/1932296820978423" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_pxd4y8M">J Diabetes Sci Technol</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Polonsky WH, Fortmann AL. Impact of real-time CGM data sharing on quality of life in the caregivers of adults and children with type 1 diabetes. J Diabetes Sci Technol. 2020. https://doi.org/10. 1177/1932296820978423.</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_Ku3Fc3j">Continuous glucose monitoring and metrics for clinical trials: an international consensus statement</title>
		<author>
			<persName><forename type="first">T</forename><surname>Battelino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Amiel</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(22)00319-9</idno>
		<ptr target="https://doi.org/10.1016/s2213-8587(22)00319-9" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qYbu92X">Lancet Diabetes Endocrinol</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Battelino T, Alexander CM, Amiel SA, et al. Con- tinuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2022. https://doi.org/10.1016/ s2213-8587(22)00319-9.</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_C6Dm2SF">Susceptibility of interstitial continuous glucose monitor performance to sleeping position</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Mensh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Wisniewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Burnett</surname></persName>
		</author>
		<idno type="DOI">10.1177/193229681300700408</idno>
		<ptr target="https://doi.org/10.1177/193229681300700408" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_U769TAD">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="863" to="870" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mensh BD, Wisniewski NA, Neil BM, Burnett DR. Susceptibility of interstitial continuous glucose monitor performance to sleeping position. J Dia- betes Sci Technol. 2013;7:863-70. https://doi.org/ 10.1177/193229681300700408.</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_4srwVz6">Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schabert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Browne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mosely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Speight</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40271-012-0001-0</idno>
		<ptr target="https://doi.org/10.1007/s40271-012-0001-0" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_spVKxZA">Patient</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6:1-10. https://doi.org/10.1007/ s40271-012-0001-0.</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_CjYHUmt">FreeStyle Libre for glucose monitoring</title>
		<idno type="DOI">10.47583/ijpsrr.2025.v85i3.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q9s84A9">MIB</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>Medtech innovation briefing</note>
	<note type="raw_reference">FreeStyle Libre for glucose monitoring. Medtech innovation briefing [MIB110] 2017.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title level="m" type="main" xml:id="_3MYfcqs">Type 1 diabetes in adults: diagnosis and management NICE guideline Published: 26</title>
		<idno type="DOI">10.1136/bmj.h4188</idno>
		<ptr target="https://www.nice.org.uk/guidance/ng17.54" />
		<imprint>
			<date type="published" when="2015-08-17">August 2015. 17 August 2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Type 1 diabetes in adults: diagnosis and manage- ment NICE guideline Published: 26 August 2015. Last updated: 17 August 2022. https://www.nice. org.uk/guidance/ng17. 54</note>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main" xml:id="_qGrekWh">Type 2 diabetes in adults: management NICE guideline</title>
		<idno type="DOI">10.1002/psb.1450</idno>
		<ptr target="https://www.nice.org.uk/guidance/ng28" />
		<imprint/>
	</monogr>
	<note>Published: 2 December 2015. Last updated: 29 June 2022</note>
	<note type="raw_reference">Type 2 diabetes in adults: management NICE guideline. Published: 2 December 2015. Last upda- ted: 29 June 2022. https://www.nice.org.uk/ guidance/ng28.</note>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main" xml:id="_zWCZygv">Diabetes (type 1 and type 2) in children and young people: diagnosis and management NICE guideline</title>
		<idno type="DOI">10.1136/bmj.p2072</idno>
		<ptr target="https://www.nice.org.uk/guidance/ng18" />
		<imprint>
			<date type="published" when="2015-08">August 2015. May 2023</date>
		</imprint>
	</monogr>
	<note>Published: 1 Last updated: 11</note>
	<note type="raw_reference">Diabetes (type 1 and type 2) in children and young people: diagnosis and management NICE guideline. Published: 1 August 2015. Last updated: 11 May 2023. https://www.nice.org.uk/guidance/ng18.</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_3z2F7Pu">7. Diabetes Technology: Standards of Medical Care in Diabetes-2019</title>
		<idno type="DOI">10.2337/dc19-s007</idno>
		<ptr target="https://doi.org/10.2337/dc19-s007" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jVjk5hS">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="71" to="80" />
			<date type="published" when="2018">2018</date>
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association. 7. Diabetes Tech- nology: Standards of Medical Care in Diabetes- 2019. Diabetes Care 2018;42:71-80. https://doi.org/ 10.2337/dc19-s007.</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_YJKA9b2">Diabetes Technology: Standards of Medical Care in Diabetes-2022</title>
		<author>
			<persName><forename type="first">B</forename><surname>Draznin</surname></persName>
			<affiliation>
				<orgName type="collaboration">American Diabetes Association Professional Practice Committee</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Aroda</surname></persName>
			<affiliation>
				<orgName type="collaboration">American Diabetes Association Professional Practice Committee</orgName>
			</affiliation>
		</author>
		<idno type="DOI">10.2337/dc22-s007</idno>
		<ptr target="https://doi.org/10.2337/dc22-s007" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_z7Se9gz">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="97" to="112" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 7. Diabetes Technology: Standards of Medical Care in Dia- betes-2022. Diabetes Care 2021;45:S97-112. https://doi.org/10.2337/dc22-s007.</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_YVjpkDH">The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</title>
		<author>
			<persName><forename type="first">Rig</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Devries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hess-Fischl</surname></persName>
		</author>
		<idno type="DOI">10.2337/dci21-0043</idno>
		<ptr target="https://doi.org/10.2337/dci21-0043" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_s45YNMt">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2589" to="2625" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A con- sensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44: 2589-625. https://doi.org/10.2337/dci21-0043.</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_fa3cBTP">ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tauschmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Forlenza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hood</surname></persName>
		</author>
		<idno type="DOI">10.1111/pedi.13451</idno>
		<ptr target="https://doi.org/10.1111/pedi.13451" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_fJzepwS">Pediatr Diabetes</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1390" to="1405" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tauschmann M, Forlenza G, Hood K, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: glucose monitoring. Pediatr Diabetes. 2022;23:1390-405. https://doi.org/10.1111/pedi. 13451.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_scWDc9g">ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, young people with diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Codner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Craig</surname></persName>
		</author>
		<idno type="DOI">10.1111/pedi.13455</idno>
		<ptr target="https://doi.org/10.1111/pedi.13455" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gVscQ3r">Pediatr Diabetes</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1270" to="1276" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: glycemic tar- gets and glucose monitoring for children, adoles- cents, young people with diabetes. Pediatr Diabetes. 2022;23:1270-6. https://doi.org/10.1111/ pedi.13455.</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_2jyJMsK">Clinical Practice Consensus Guidelines 2022: management of the child, adolescent, and young adult with diabetes in limited resource settings</title>
		<author>
			<persName><forename type="first">A</forename><surname>Virmani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Brink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Middlehurst</surname></persName>
		</author>
		<idno type="DOI">10.1111/pedi.13456</idno>
		<ptr target="https://doi.org/10.1111/pedi.13456" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gSwcd7t">Pediatr Diabetes</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1529" to="1551" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Virmani A, Brink SJ, Middlehurst A, et al. Clinical Practice Consensus Guidelines 2022: man- agement of the child, adolescent, and young adult with diabetes in limited resource settings. Pediatr Diabetes. 2022;23:1529-51. https://doi.org/10. 1111/pedi.13456.</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_KsRTECF">Stages of type 1 diabetes in children and adolescents</title>
		<author>
			<persName><forename type="first">Rej</forename><surname>Besser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Bell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Couper</surname></persName>
		</author>
		<idno type="DOI">10.1111/pedi.13410</idno>
		<ptr target="https://doi.org/10.1111/pedi.13410" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_RfQDn7U">Pediatr Diabetes</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Besser REJ, Bell KJ, Couper JJ, et al. Stages of type 1 diabetes in children and adolescents. Pediatr Dia- betes. 2022. https://doi.org/10.1111/pedi.13410.</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_ZYjKuUV">Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Aroda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Collins</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-022-05787-2</idno>
		<ptr target="https://doi.org/10.1007/s00125-022-05787-2" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_DxehbJW">Diabetologia</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A con- sensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022. https://doi. org/10.1007/s00125-022-05787-2.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_SQPrHeu">American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus</title>
		<author>
			<persName><forename type="first">G</forename><surname>Grunberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sherr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Allende</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eprac.2021.04.008</idno>
		<ptr target="https://doi.org/10.1016/j.eprac.2021.04.008" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qT2wKXy">Endocr Pract</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="505" to="537" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mel- litus. Endocr Pract. 2021;27:505-37. https://doi.org/ 10.1016/j.eprac.2021.04.008.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_htnu6cG">Response to American Association of clinical endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus</title>
		<author>
			<persName><forename type="first">N</forename><surname>Virdi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eprac.2021.07.006</idno>
		<ptr target="https://doi.org/10.1016/j.eprac.2021.07.006" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2372DaN">Endocr Pract</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">1062</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Virdi N. Response to American Association of clin- ical endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27:1062. https://doi.org/10.1016/j.eprac. 2021.07.006.</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_hw9mfMj">Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management</title>
		<author>
			<persName><forename type="first">Apk</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yoo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2023.110718</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2023.110718" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZVcNHAE">Diabetes Res Clin Pract</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kong APK, Lim S, Yoo SH, et al. Asia-Pacific con- sensus recommendations for application of contin- uous glucose monitoring in diabetes management. Diabetes Res Clin Pract. 2023. https://doi.org/10. 1016/j.diabres.2023.110718.</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_XBUThY8">JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods</title>
		<author>
			<persName><forename type="first">Jdrf</forename><surname>Cgm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Study</forename><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2007.0302</idno>
		<ptr target="https://doi.org/10.1089/dia.2007.0302" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ez8gy8U">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="310" to="321" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther. 2008;10:310-21. https://doi.org/10. 1089/dia.2007.0302.</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_vzyHR9e">Therapy adjustments based on trend arrows using continuous glucose monitoring systems</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Sengbusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kro ¨ger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<idno type="DOI">10.1177/1932296818822539</idno>
		<ptr target="https://doi.org/10.1177/1932296818822539" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_MhC698S">J Diabetes Sci Technol</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ziegler R, von Sengbusch S, Kro ¨ger J, et al. Therapy adjustments based on trend arrows using continu- ous glucose monitoring systems. J Diabetes Sci Technol. 2019. https://doi.org/10.1177/ 1932296818822539.</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_fyby3Kh">Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey</title>
		<author>
			<persName><forename type="first">K</forename><surname>Akram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Pedersen-Bjergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Borch-Johnsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thorsteinsson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jdiacomp.2005.08.005</idno>
		<ptr target="https://doi.org/10.1016/j.jdiacomp.2005.08.005" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2XWHjE8">J Diabetes Complicat</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="402" to="408" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of sev- ere hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complicat. 2006;20: 402-8. https://doi.org/10.1016/j.jdiacomp.2005.08. 005.</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_zHQx6Tq">Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective realworld chart review study and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Desantis</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjdrc-2021-002590</idno>
		<ptr target="https://doi.org/10.1136/bmjdrc-2021-002590" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ctv49EH">BMJ Open Diabetes Res Care</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">2590</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Carlson AL, Daniel TD, DeSantis A, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real- world chart review study and meta-analysis. BMJ Open Diabetes Res Care. 2022;10:e002590. https:// doi.org/10.1136/bmjdrc-2021-002590.</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_mBS7WPJ">Flash CGM associated with event reduction in nonintensive diabetes therapy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msd</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nabutovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wright</surname></persName>
		</author>
		<idno type="DOI">10.37765/ajmc.2021.88780</idno>
		<ptr target="https://doi.org/10.37765/ajmc.2021.88780" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jS4dUwY">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="372" to="377" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Miller E, Kerr MSD, Roberts GJ, Nabutovsky Y, Wright E. Flash CGM associated with event reduc- tion in nonintensive diabetes therapy. Am J Manag Care. 2021;27:372-7. https://doi.org/10.37765/ ajmc.2021.88780.</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_JdgMCz8">Intermittent use of continuous glucose monitoring: expanding the clinical value of CGM</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ziegler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Heinemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Freckmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hinzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kulzer</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296820905577</idno>
		<ptr target="https://doi.org/10.1177/1932296820905577" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_nVVQWyf">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="684" to="694" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ziegler R, Heinemann L, Freckmann G, Schnell O, Hinzmann R, Kulzer B. Intermittent use of contin- uous glucose monitoring: expanding the clinical value of CGM. J Diabetes Sci Technol. 2021;15: 684-94. https://doi.org/10.1177/ 1932296820905577.</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_h3vUQYk">Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Brinkworth</surname></persName>
		</author>
		<idno type="DOI">10.1111/jdi.12807</idno>
		<ptr target="https://doi.org/10.1111/jdi.12807" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_YM8RRxn">J Diabetes Invest</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="713" to="725" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Taylor PJ, Thompson CH, Brinkworth GD. Effec- tiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review. J Diabetes Invest. 2018;9:713-25. https://doi.org/10.1111/jdi.12807.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_jaUDac9">Episodic realtime CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kipnes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Beck</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-021-01086-y</idno>
		<ptr target="https://doi.org/10.1007/s13300-021-01086-y" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_nY3UmEN">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2089" to="2099" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Price DA, Deng Q, Kipnes M, Beck SE. Episodic real- time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial. Diabetes Ther. 2021;12:2089-99. https://doi.org/10.1007/ s13300-021-01086-y.</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_E8aSbnd">Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vigersky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1111/dom.14852</idno>
		<ptr target="https://doi.org/10.1111/dom.14852" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_kgkfuWS">Diabetes Obes Metab</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moon SJ, Kim K, Lee WJ, Lee MY, Vigersky R, Park C. Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-in- sulin-treated patients with type 2 diabetes: a ran- domized controlled trial. Diabetes Obes Metab. 2022. https://doi.org/10.1111/dom.14852.</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_bBjvb3q">Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Fain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Braun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Chipkin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2008.01.006</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2008.01.006" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_K5Fepz8">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="371" to="379" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 dia- betes: a randomized clinical trial. Diabetes Res Clin Pract. 2008;80:371-9. https://doi.org/10.1016/j. diabres.2008.01.006.</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_uwE9TUA">Hypoglycemia in type 2 diabetesmore common than you think</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Gehlaut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Dogbey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Marling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Shubrook</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296815581052</idno>
		<ptr target="https://doi.org/10.1177/1932296815581052" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_q6jfNpv">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="999" to="1005" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes- more common than you think. J Diabetes Sci Technol. 2015;9:999-1005. https://doi.org/10. 1177/1932296815581052.</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_hfEEVyR">A modelling study of the budget impact of improved glycaemic control in adults with type 1 diabetes in the UK</title>
		<author>
			<persName><forename type="first">P</forename><surname>Choudhary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Portu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Delbaere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Pickup</surname></persName>
		</author>
		<idno type="DOI">10.1111/dme.13924</idno>
		<ptr target="https://doi.org/10.1111/dme.13924" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_3N4EjQv">Diabetic Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="988" to="994" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choudhary P, Portu S, Delbaere A, Lyon J, Pickup JC. A modelling study of the budget impact of improved glycaemic control in adults with type 1 diabetes in the UK. Diabetic Med. 2019;36:988-94. https://doi.org/10.1111/dme.13924.</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_pBz8H8x">Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technolofor adults with type 1 diabetes in Canada: a modeling study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Rotondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Riddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Perkins</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc21-2341</idno>
		<ptr target="https://doi.org/10.2337/dc21-2341" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_W3BCqUd">Diabetes Care</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rotondi MA, Wong O, Riddell M, Perkins B. Popu- lation-level impact and cost-effectiveness of con- tinuous glucose monitoring and intermittently scanned continuous glucose monitoring technolo- for adults with type 1 diabetes in Canada: a modeling study. Diabetes Care. 2022. https://doi. org/10.2337/dc21-2341.</note>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main" xml:id="_ZRaKY3E">Long-term costeffectiveness the Dexcom G6 real-time continuous glucose monitoring system compared with selfmonitoring of blood glucose in people with type 1 diabetes in France</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Isitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smith-Palmer</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-020-00959-y</idno>
		<ptr target="https://doi.org/10.1007/s13300-020-00959-y" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_6fEE8Dv">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="235" to="246" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roze S, Isitt JJ, Smith-Palmer J, et al. Long-term cost- effectiveness the Dexcom G6 real-time continuous glucose monitoring system compared with self- monitoring of blood glucose in people with type 1 diabetes in France. Diabetes Ther. 2021;12:235-46. https://doi.org/10.1007/s13300-020-00959-y.</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main" xml:id="_AyVAfRC">Long-term cost-effectiveness of Dexcom G6 realtime continuous glucose monitoring versus selfmonitoring of blood glucose in patients with type 1 diabetes in the UK</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Isitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smith-Palmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Javanbakht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lynch</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc19-2213</idno>
		<ptr target="https://doi.org/10.2337/dc19-2213" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_6btNsYC">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="2411" to="2417" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of Dexcom G6 real- time continuous glucose monitoring versus self- monitoring of blood glucose in patients with type 1 diabetes in the UK. Diabetes Care. 2020;43:2411-7. https://doi.org/10.2337/dc19-2213.</note>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main" xml:id="_AwaZK7x">The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Fonda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Munakata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Powers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Vigersky</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296816628547</idno>
		<ptr target="https://doi.org/10.1177/1932296816628547" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_UPGDkRN">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="898" to="904" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol. 2016;10:898-904. https://doi.org/10.1177/1932296816628547.</note>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main" xml:id="_G5GhX95">Clinical and economic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sierra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Gill</surname></persName>
		</author>
		<idno type="DOI">10.1080/13696998.2017.1390474</idno>
		<ptr target="https://doi.org/10.1080/13696998.2017.1390474" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_en2Z5qx">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="225" to="230" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sierra JA, Shah M, Gill MS, et al. Clinical and eco- nomic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data. J Med Econ. 2018;21:225-30. https://doi.org/10.1080/13696998.2017.1390474.</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main" xml:id="_Y4BRtpv">Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yaron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Roitman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aharon</forename><forename type="middle">-</forename><surname>Hananel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.2337/dc18-0166</idno>
		<ptr target="https://doi.org/10.2337/dc18-0166" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_MbHB7fd">Diabetes Care</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019. https://doi.org/10.2337/dc18-0166.</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main" xml:id="_WSrvtFJ">Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ahlqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Storm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ka</forename></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(18)30051-2</idno>
		<ptr target="https://doi.org/10.1016/s2213-8587(18)30051-2" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_3jzBZ2w">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="361" to="369" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ahlqvist E, Storm P, Ka ¨ra ¨ja ¨ma ¨ki A, et al. Novel subgroups of adult-onset diabetes and their associ- ation with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6: 361-9. https://doi.org/10.1016/s2213- 8587(18)30051-2.</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main" xml:id="_gTsMSFN">Glucotypes reveal new patterns of glucose dysregulation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Perelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Breschi</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pbio.2005143</idno>
		<ptr target="https://doi.org/10.1371/journal.pbio.2005143" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_YjWNmQH">Plos Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">2005143</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation. Plos Biol. 2018;16:e2005143. https://doi.org/10.1371/ journal.pbio.2005143.</note>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main" xml:id="_cpKjeUW">Reasons for not intensifying medications: differentiating &apos;&apos;clinical inertia&apos;&apos; from appropriate care</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Safford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Shewchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Qu</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11606-007-0433-8</idno>
		<ptr target="https://doi.org/10.1007/s11606-007-0433-8" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZPbJGYs">J Gen Intern Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1648" to="1655" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating &apos;&apos;clin- ical inertia&apos;&apos; from appropriate care. J Gen Intern Med. 2007;22:1648-55. https://doi.org/10.1007/ s11606-007-0433-8.</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main" xml:id="_qUfTu6Q">Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin</title>
		<author>
			<persName><forename type="first">K</forename><surname>Khunti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nikolajsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Thorsted</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<idno type="DOI">10.1111/dom.12626</idno>
		<ptr target="https://doi.org/10.1111/dom.12626" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_GG8BVJQ">Diabetes Obes Metab</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK. Clinical inertia in intensifying therapy among people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016. https://doi.org/10.1111/dom.12626.</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main" xml:id="_cJQvGaq">Therapeutic inertia amongst general practitioners with interest in diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Seidu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Than</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kar</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pcd.2017.09.001</idno>
		<ptr target="https://doi.org/10.1016/j.pcd.2017.09.001" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_SHqe9cM">Prim Care Diabetes</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="87" to="91" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Seidu S, Than T, Kar D, et al. Therapeutic inertia amongst general practitioners with interest in dia- betes. Prim Care Diabetes. 2018;12:87-91. https:// doi.org/10.1016/j.pcd.2017.09.001.</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main" xml:id="_jwgyGFV">Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association&apos;s standards of medical care in diabetes clinical guideline</title>
		<author>
			<persName><forename type="first">K</forename><surname>Doyle-Delgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Chamberlain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Shubrook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Skolnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Trujillo</surname></persName>
		</author>
		<idno type="DOI">10.7326/m20-2470</idno>
		<ptr target="https://doi.org/10.7326/m20-2470" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_7527JAK">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="813" to="821" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association&apos;s standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020;173:813-21. https://doi.org/10. 7326/m20-2470.</note>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main" xml:id="_G4Pahdb">Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Khunti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pocock</surname></persName>
		</author>
		<idno type="DOI">10.1111/dom.13088</idno>
		<ptr target="https://doi.org/10.1111/dom.13088" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gJ7Dbqh">Diabetes Obes Metab</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="427" to="437" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20:427-37. https://doi. org/10.1111/dom.13088.</note>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main" xml:id="_RfFnjS9">Time to treatment intensification to reduce diabetes-related complications: a post hoc study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kaewbut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kosachunhanun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Phrommintikul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chinwong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chinwong</surname></persName>
		</author>
		<idno type="DOI">10.3390/healthcare10091673</idno>
		<ptr target="https://doi.org/10.3390/healthcare10091673" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_b4tjWxj">Healthcare</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1673</biblScope>
			<date type="published" when="2022">2022</date>
			<pubPlace>Basel)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaewbut P, Kosachunhanun N, Phrommintikul A, Chinwong D, Hall JJ, Chinwong S. Time to treat- ment intensification to reduce diabetes-related complications: a post hoc study. Healthcare (Basel). 2022;10:1673. https://doi.org/10.3390/ healthcare10091673.</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main" xml:id="_rkMSVbh">Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Thorsted</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Wolden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Khunti</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12933-015-0260-x</idno>
		<ptr target="https://doi.org/10.1186/s12933-015-0260-x" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_xZukSjq">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">100</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100. https:// doi.org/10.1186/s12933-015-0260-x.</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main" xml:id="_qUAz7fT">Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Valentine</surname></persName>
		</author>
		<idno type="DOI">10.1080/13696998.2019.1645018</idno>
		<ptr target="https://doi.org/10.1080/13696998.2019.1645018" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Ss73JQr">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1" to="1" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bain SC, Hansen BB, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2019;23:1-1. https://doi.org/10.1080/13696998.2019.1645018.</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main" xml:id="_KBDj5qx">The societal impact of early intensified treatment in patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">F</forename><surname>Tsotra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kappel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Peristeris</surname></persName>
		</author>
		<idno type="DOI">10.2217/cer-2022-0110</idno>
		<ptr target="https://doi.org/10.2217/cer-2022-0110" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Pg9mXnz">J Comp Effect Res</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsotra F, Kappel M, Peristeris P, et al. The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. J Comp Effect Res. 2022. https://doi.org/10.2217/cer-2022-0110.</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main" xml:id="_JzTUk9w">Psychological insulin resistance in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Polonsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Villa-Caballero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Edelman</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.28.10.2543</idno>
		<ptr target="https://doi.org/10.2337/diacare.28.10.2543" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_wcPuRRG">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2543" to="2545" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care. 2005;28:2543-5. https://doi.org/10.2337/diacare. 28.10.2543.</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main" xml:id="_cjt66jM">Use of the FreeStyle LibreÒ system in diabetes treatment for people with T2D: results from a retrospective cohort study using Canadian private payer claims database</title>
		<author>
			<persName><forename type="first">S</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Levrat-Guillen</surname></persName>
		</author>
		<idno type="DOI">10.2337/db22-680-p</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Qf969J6">Diabetes Obesity Metab</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1704" to="1713" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Harris S, Levrat-Guillen F. Use of the FreeStyle LibreÒ system in diabetes treatment for people with T2D: results from a retrospective cohort study using Canadian private payer claims database. Diabetes Obesity Metab. 2023:25(6):1704-13.</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main" xml:id="_YRJSydB">Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Simonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Martens</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296821998724</idno>
		<ptr target="https://doi.org/10.1177/1932296821998724" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_XDaqPYm">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="539" to="545" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Simonson GD, Bergenstal RM, Johnson ML, David- son JL, Martens TW. Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care. J Diabetes Sci Technol. 2021;15:539-45. https://doi.org/10.1177/ 1932296821998724.</note>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main" xml:id="_NsSzWGd">Effect of pharmacist-driven professional continuous glucose monitoring in adults with uncontrolled dia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Sherrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Houpt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Richter</surname></persName>
		</author>
		<idno type="DOI">10.18553/jmcp.2020.26.5.600</idno>
		<ptr target="https://doi.org/10.18553/jmcp.2020.26.5.600.100" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_kH6ZHHY">J Manag Care Spec</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="600" to="609" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sherrill CH, Houpt CT, Dixon EM, Richter SJ. Effect of pharmacist-driven professional continuous glu- cose monitoring in adults with uncontrolled dia- J Manag Care Spec. 2020;26:600-9. https:// doi.org/10.18553/jmcp.2020.26.5.600. 100</note>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main" xml:id="_agr8bMH">The impact of flash glucose monitoring on adults with type 1 diabetes&apos; eating habits and relationship with food</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Koebbel</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2022.110230</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2022.110230.101" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_UfVWcY9">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="page">110230</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wallace T, Heath J, Koebbel C. The impact of flash glucose monitoring on adults with type 1 diabetes&apos; eating habits and relationship with food. Diabetes Res Clin Pract. 2023;196:110230. https://doi.org/10. 1016/j.diabres.2022.110230. 101</note>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main" xml:id="_rN4PSJW">The AH-HA! project: transforming group diabetes self-management education through the addition of flash glucose monitoring</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Polonsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Fortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Guzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Funnell</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2022.0419</idno>
		<ptr target="https://doi.org/10.1089/dia.2022.0419.102" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_pSHVXRp">Diabetes Technol Ther</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Polonsky WH, Fortmann AL, Soriano EC, Guzman SJ, Funnell MM. The AH-HA! project: transforming group diabetes self-management education through the addition of flash glucose monitoring. Diabetes Technol Ther. 2022. https://doi.org/10.1089/dia. 2022.0419. 102</note>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main" xml:id="_cJb4wu8">The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">-A ´vila</forename><surname>Rivera</surname></persName>
		</author>
		<author>
			<persName><surname>Da</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Esquivel-Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Salazar-Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Doubova</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12902-021-00742-5</idno>
		<ptr target="https://doi.org/10.1186/s12902-021-00742-5.103" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_9CDQRJf">BMC Endocr Disord</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">79</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rivera-A ´vila DA, Esquivel-Lu AI, Salazar-Lozano CR, Jones K, Doubova SV. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC Endocr Disord. 2021;21:79. https://doi.org/10.1186/s12902-021- 00742-5. 103</note>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main" xml:id="_cVjMXdF">Personal continuous glucose monitoring use among adults with type 2 diabetes: clinical efficacy and economic impacts</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Oser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Litchman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11892-021-01408-1</idno>
		<ptr target="https://doi.org/10.1007/s11892-021-01408-1.104" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_MexFgb8">Curr Diabetes Rep</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">49</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oser TK, Litchman ML, Allen NA, et al. Personal continuous glucose monitoring use among adults with type 2 diabetes: clinical efficacy and economic impacts. Curr Diabetes Rep. 2021;21:49. https://doi. org/10.1007/s11892-021-01408-1. 104</note>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main" xml:id="_NvP93Sj">Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Msd</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Souto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nabutovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ib ;</forename><surname>Hirsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Baser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xie</surname></persName>
		</author>
		<idno type="DOI">10.2147/ppa.s49287</idno>
		<ptr target="https://doi.org/10.2147/ppa.s49287.107" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_nYnbgND">Patient Prefer Adher</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="951" to="960" />
			<date type="published" when="2013">2021. 2020. 2013</date>
			<pubPlace>Haute Autorite Sante</pubPlace>
		</imprint>
	</monogr>
	<note>FreeStyle Libre 2 Flash Glucose Monitoring System Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes J Endocr Soc</note>
	<note type="raw_reference">Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5:13. https://doi.org/10.1210/jendso/ bvab013. 105. FreeStyle Libre 2 Flash Glucose Monitoring System. Haute Autorite Sante 2020. 106. Miao R, Wei W, Baser O, Xie L. Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Patient Prefer Adher. 2013;7:951-60. https://doi.org/10. 2147/ppa.s49287. 107</note>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main" xml:id="_CUFQF8W">Persistence with basal insulin and frequency of hypoglycemia requiring hospitalization in patients with type 2 diabetes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Roussel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Detournay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Boultif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bahloul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Teissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Charbonnel</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-020-00874-2</idno>
		<ptr target="https://doi.org/10.1007/s13300-020-00874-2.108" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_vas4w9p">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1861" to="1872" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roussel R, Detournay B, Boultif Z, Bahloul A, Teis- sier C, Charbonnel B. Persistence with basal insulin and frequency of hypoglycemia requiring hospital- ization in patients with type 2 diabetes. Diabetes Ther. 2020;11:1861-72. https://doi.org/10.1007/ s13300-020-00874-2. 108</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main" xml:id="_zApFMKN">Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: an exploratory analysis from a UK realworld sample</title>
		<author>
			<persName><forename type="first">I</forename><surname>Idris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gulati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perez-Nieves</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.pcd.2018.09.002</idno>
		<ptr target="https://doi.org/10.1016/j.pcd.2018.09.002.109" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_bJZYdgW">Prim Care Diabetes</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="106" to="112" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Idris I, Gulati K, Perez-Nieves M, et al. Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: an exploratory analysis from a UK real- world sample. Prim Care Diabetes. 2019;13:106-12. https://doi.org/10.1016/j.pcd.2018.09.002. 109</note>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main" xml:id="_ejvCKeh">The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin</title>
		<author>
			<persName><forename type="first">G</forename><surname>Aleppo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bailey</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc21-1304</idno>
		<ptr target="https://doi.org/10.2337/dc21-1304.110" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_FUAKFwn">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="2729" to="2737" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aleppo G, Beck RW, Bailey R, et al. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insu- lin. Diabetes Care. 2021;44:2729-37. https://doi. org/10.2337/dc21-1304. 110</note>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main" xml:id="_BYjYGcf">The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Beca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Beharry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Tsoukas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zarruk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abitbol</surname></persName>
		</author>
		<idno type="DOI">10.1177/14791641211021374</idno>
		<ptr target="https://doi.org/10.1177/14791641211021374.111" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_9t9c7tp">Diabetes Vasc Dis Re</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">14791641211021374</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes man- aged with basal insulin in Canada: a retrospective real-world chart review study. Diabetes Vasc Dis Re. 2021;18:14791641211021374. https://doi.org/10. 1177/14791641211021374. 111</note>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main" xml:id="_TGFThwW">Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality</title>
		<author>
			<persName><forename type="first">A</forename><surname>Moran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dunitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saeed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Holme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Thomas</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc09-0586</idno>
		<ptr target="https://doi.org/10.2337/dc09-0586.112" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_px3V4AG">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1626" to="1631" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626-31. https://doi.org/10. 2337/dc09-0586. 112</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main" xml:id="_BcUAXe8">Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Alves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Della-Manna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ctm</forename><surname>Albuquerque</surname></persName>
		</author>
		<idno type="DOI">10.1515/jpem-2019-0484</idno>
		<ptr target="https://doi.org/10.1515/jpem-2019-0484.113" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_an7JK7r">J Pediatr Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="835" to="843" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Alves C, Della-Manna T, Albuquerque CTM. Cystic fibrosis-related diabetes: an update on pathophysi- ology, diagnosis, and treatment. J Pediatr Endocri- nol Metab. 2020;33:835-43. https://doi.org/10. 1515/jpem-2019-0484. 113</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main" xml:id="_4nmjFxn">Cystic fibrosisrelated diabetes: the unmet need</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mendez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Surani</surname></persName>
		</author>
		<idno type="DOI">10.4239/wjd.v11.i6.213</idno>
		<ptr target="https://doi.org/10.4239/wjd.v11.i6.213.114" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5mc7yHK">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="213" to="217" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pozo L, Bello F, Mendez Y, Surani S. Cystic fibrosis- related diabetes: the unmet need. World J Diabetes. 2020;11:213-7. https://doi.org/10.4239/wjd.v11.i6. 213. 114</note>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main" xml:id="_4KMM7cG">Diabetes as a determinant of mortality in cystic fibrosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chamnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bsf</forename><surname>Shine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Haworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Adler</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc09-1215</idno>
		<ptr target="https://doi.org/10.2337/dc09-1215.115" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_awt8mXc">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="311" to="316" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chamnan P, Shine BSF, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33:311-6. https://doi. org/10.2337/dc09-1215. 115</note>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main" xml:id="_636cZFR">Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic fibrosis: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pallin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Soldatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Teede</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcte.2022.100305</idno>
		<ptr target="https://doi.org/10.1016/j.jcte.2022.100305.116" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_sqUH2pP">J Clin Transl Endocrinol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">100305</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kumar S, Pallin M, Soldatos G, Teede H. Compar- ison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detec- tion of dysglycemia in cystic fibrosis: a systematic review. J Clin Transl Endocrinol. 2022;30:100305. https://doi.org/10.1016/j.jcte.2022.100305. 116</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main" xml:id="_ShDMD6b">Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zorron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fal</forename><surname>Marson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Morcillo</surname></persName>
		</author>
		<idno type="DOI">10.36416/1806-3756/e20210307</idno>
		<ptr target="https://doi.org/10.36416/1806-3756/e20210307.117" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NyAMYy8">J Bras Pneumol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">202</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zorron M, Marson FAL, Morcillo AM, et al. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical out- come? J Bras Pneumol 2022;48:202. https://doi.org/ 10.36416/1806-3756/e20210307. 117</note>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main" xml:id="_Cx38Sqw">Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Scully</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Sherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Martin</surname></persName>
		</author>
		<idno type="DOI">10.1210/clinem/dgab857</idno>
		<ptr target="https://doi.org/10.1210/clinem/dgab857.118" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_A2nfbee">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="1444" to="1454" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scully KJ, Sherwood JS, Martin K, et al. Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab. 2021;107: e1444-54. https://doi.org/10.1210/clinem/ dgab857. 118</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main" xml:id="_pdnP7Vg">Continuous glucose monitoring versus selfmonitoring of blood glucose in the management of cystic related diabetes: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Soldatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ranasinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Teede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pallin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcf.2022.07.013</idno>
		<ptr target="https://doi.org/10.1016/j.jcf.2022.07.013.119" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_UzxZpnM">J Cyst Fibros</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M. Continuous glucose monitoring versus self- monitoring of blood glucose in the management of cystic related diabetes: a systematic review and meta-analysis. J Cyst Fibros. 2022. https://doi. org/10.1016/j.jcf.2022.07.013. 119</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main" xml:id="_G7mutSN">Continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gojsina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Minic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Todorovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Soldatovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sovtic</surname></persName>
		</author>
		<idno type="DOI">10.3389/fped.2021.659728</idno>
		<ptr target="https://www.cysticfibrosis.org.uk/sites/default/files/2022-10/CFT_2021-Annual-Data-Report-WEB.pdf" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_CrGRFRb">Front Pediatr</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">121</biblScope>
			<date type="published" when="2021">2021. 2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gojsina B, Minic P, Todorovic S, Soldatovic I, Sovtic A. Continuous glucose monitoring as a valuable tool in the early detection of diabetes related to cystic fibrosis. Front Pediatr. 2021;9: 659728. https://doi.org/10.3389/fped.2021.659728. 120. UK Cystic Fibrosis Registry. 2021 Annual Data Report. https://www.cysticfibrosis.org.uk/sites/ default/files/2022-10/CFT_2021-Annual-Data- Report-WEB.pdf, 1.24 CF-related diabetes, 34. 121</note>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main" xml:id="_Rgjf4td">Use of real-time continuous glucose monitoring improves glycemic control and other clinical outcomes in type 2 diabetes patients treated with less intensive therapy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Grace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Salyer</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0212</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0212.122" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_PcWq4p9">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="26" to="31" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Grace T, Salyer J. Use of real-time continuous glu- cose monitoring improves glycemic control and other clinical outcomes in type 2 diabetes patients treated with less intensive therapy. Diabetes Tech- nol Ther. 2022;24:26-31. https://doi.org/10.1089/ dia.2021.0212. 122</note>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main" xml:id="_6eYDwpA">IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Karuranga</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2018.02.023</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2018.02.023.123" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2uAe2Pk">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="271" to="281" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81. https://doi.org/10.1016/j. diabres.2018.02.023. 123</note>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main" xml:id="_pxqYuJt">Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Calhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0494</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0494.124" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_eTHcVEt">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="299" to="306" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bao S, Bailey R, Calhoun P, Beck RW. Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin. Diabetes Technol Ther. 2022;24:299-306. https:// doi.org/10.1089/dia.2021.0494. 124</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main" xml:id="_svAnj5j">Reduced acute diabetes events after FreeStyle LibreÒ system initiation in people 65 years or older with type 2 diabetes on intensive insulin therapy in France</title>
		<author>
			<persName><forename type="first">B</forename><surname>Guerci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Levrat-Guillen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vicaut</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2023.0034</idno>
		<ptr target="https://doi.org/10.1089/dia.2023.0034.125" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_qq45MQK">Diabet Technol Ther</title>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guerci B, Levrat-Guillen F, Vicaut E, et al. Reduced acute diabetes events after FreeStyle LibreÒ system initiation in people 65 years or older with type 2 diabetes on intensive insulin therapy in France. Diabet Technol Ther. 2023. https://doi.org/10. 1089/dia.2023.0034. 125</note>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main" xml:id="_WEBGFfm">Frequent hypoglycemia among elderly patients with poor glycemic control</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Munshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Segal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Suhl</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinternmed.2010.539</idno>
		<ptr target="https://doi.org/10.1001/archinternmed.2010.539.126" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_K7VWHjP">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="362" to="364" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171: 362-4. https://doi.org/10.1001/archinternmed. 2010.539. 126</note>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main" xml:id="_DtW8J7y">HbA1c and risk of severe hypoglycemia in type 2 diabetes</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Lipska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Warton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc13-0610</idno>
		<ptr target="https://doi.org/10.2337/dc13-0610.127" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZHtYBbH">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="3535" to="3542" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes. Diabetes Care. 2013;36:3535-42. https://doi.org/10. 2337/dc13-0610. 127</note>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main" xml:id="_mNm22xG">Diabetes in the elderly</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Meneilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tessier</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1464-5491.1995.tb00405.x</idno>
		<ptr target="https://doi.org/10.1111/j.1464-5491.1995.tb00405.x.128" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_QTm6AAU">Diabetic Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="949" to="960" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Meneilly GS, Tessier D. Diabetes in the elderly. Diabetic Med. 1995;12:949-60. https://doi.org/10. 1111/j.1464-5491.1995.tb00405.x. 128</note>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main" xml:id="_cvxcS64">Diabetes in elderly adults</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Meneilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tessier</surname></persName>
		</author>
		<idno type="DOI">10.1093/gerona/56.1.m5</idno>
		<ptr target="https://doi.org/10.1093/gerona/56.1.m5.129" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_AuQTsfk">J Gerontol Ser</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="5" to="13" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol Ser. 2001;56:M5-13. https://doi.org/10. 1093/gerona/56.1.m5. 129</note>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main" xml:id="_Nt2WqTE">Multiple complications and frequent severe hypoglycaemia in &apos;elderly&apos; and &apos;old&apos; patients with type 1 diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schu ¨tt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E-M</forename><surname>Fach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Seufert</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1464-5491.2012.03681.x</idno>
		<ptr target="https://doi.org/10.1111/j.1464-5491.2012.03681.x.130" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_bg4ahhQ">Diabetic Med</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="176" to="179" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schu ¨tt M, Fach E-M, Seufert J, et al. Multiple com- plications and frequent severe hypoglycaemia in &apos;elderly&apos; and &apos;old&apos; patients with type 1 diabetes. Diabetic Med. 2012;29:e176-9. https://doi.org/10. 1111/j.1464-5491.2012.03681.x. 130</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main" xml:id="_mrbRhyE">Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: a study from the fractures and fall injuries in the elderly cohort (FRAILCO)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Wallander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Axelsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lundh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lorentzon</surname></persName>
		</author>
		<idno type="DOI">10.1002/jbmr.3002</idno>
		<ptr target="https://doi.org/10.1002/jbmr.3002.131" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_b53xy83">J Bone Miner Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="449" to="460" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 diabetes and risk of hip frac- tures and non-skeletal fall injuries in the elderly: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res. 2017;32:449-60. https://doi.org/10.1002/jbmr. 3002. 131</note>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main" xml:id="_6fUGMw9">The effects of hypoglycaemia and dementia on cardiovascular events, falls and fractures and all-cause mortality in older individuals: a retrospective cohort study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mattishent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dhatariya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Savva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Loke</surname></persName>
		</author>
		<idno type="DOI">10.1111/dom.13769</idno>
		<ptr target="https://doi.org/10.1111/dom.13769.132" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_XcgCsPx">Diabetes Obes Metab</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="2076" to="2085" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mattishent K, Richardson K, Dhatariya K, Savva GM, Fox C, Loke YK. The effects of hypoglycaemia and dementia on cardiovascular events, falls and fractures and all-cause mortality in older individu- als: a retrospective cohort study. Diabetes Obes Metab. 2019;21:2076-85. https://doi.org/10.1111/ dom.13769. 132</note>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main" xml:id="_Qt5eHSJ">Is avoidance of hypoglycaemia a better target than HbA1C in older people with diabetes?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mattishent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Loke</surname></persName>
		</author>
		<idno type="DOI">10.1111/bcp.14517</idno>
		<ptr target="https://doi.org/10.1111/bcp.14517.133" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_kD5MkZP">Brit J Clin Pharmaco</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="9" to="11" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mattishent K, Loke YK. Is avoidance of hypogly- caemia a better target than HbA1C in older people with diabetes? Brit J Clin Pharmaco. 2021;87:9-11. https://doi.org/10.1111/bcp.14517. 133</note>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main" xml:id="_hSMdnBG">Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Kosjerina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carstensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Jørgensen</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2666-7568(21)00170-7</idno>
		<ptr target="https://doi.org/10.1016/s2666-7568(21)00170-7.134" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jHRky46">Lancet Heal Longev</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="561" to="570" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kosjerina V, Carstensen B, Jørgensen ME, et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. Lancet Heal Longev. 2021;2:e561-70. https:// doi.org/10.1016/s2666-7568(21)00170-7. 134</note>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main" xml:id="_wUmrX6v">De-intensification of blood glucose lowering medication in people identified as being over-treated: a mixed methods study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ditzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Rutten</surname></persName>
		</author>
		<idno type="DOI">10.2147/ppa.s208947</idno>
		<ptr target="https://doi.org/10.2147/ppa.s208947.135" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_n9cUcDu">Patient Prefer Adher</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1775" to="1783" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hart HE, Ditzel K, Rutten GE, et al. De-intensifica- tion of blood glucose lowering medication in peo- ple identified as being over-treated: a mixed methods study. Patient Prefer Adher. 2019;13: 1775-83. https://doi.org/10.2147/ppa.s208947. 135</note>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main" xml:id="_SeDksP2">Glucose patterns in very old adults: a pilot study in a community-based population</title>
		<author>
			<persName><forename type="first">E</forename><surname>Selvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Minotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Echouffo-Tcheugui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coresh</surname></persName>
		</author>
		<idno type="DOI">10.1089/dia.2021.0156</idno>
		<ptr target="https://doi.org/10.1089/dia.2021.0156.136" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_SbNhPE3">Diabetes Technol Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="737" to="744" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Selvin E, Wang D, Tang O, Minotti M, Echouffo- Tcheugui JB, Coresh J. Glucose patterns in very old adults: a pilot study in a community-based popu- lation. Diabetes Technol Ther. 2021;23:737-44. https://doi.org/10.1089/dia.2021.0156. 136</note>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main" xml:id="_G8fmr6C">Toward defining the preclinical stages of Alzheimer&apos;s disease: recommendations from the National Institute on Aging-Alzheimer&apos;s Association workgroups on diagnostic guidelines for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sperling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Aisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Beckett</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jalz.2011.03.003</idno>
		<ptr target="https://doi.org/10.1016/j.jalz.2011.03.003.137" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_hYZ6Vr6">Alzheimer&apos;s Dementia</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="280" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&apos;s dis- ease: recommendations from the National Institute on Aging-Alzheimer&apos;s Association workgroups on diagnostic guidelines for Alzheimer&apos;s disease. Alz- heimer&apos;s Dementia. 2011;7:280-92. https://doi.org/ 10.1016/j.jalz.2011.03.003. 137</note>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main" xml:id="_6evErdB">Type 2 diabetes mellitus as a risk factor for Alzheimer&apos;s disease: review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Athanasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Melanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tsantzali</surname></persName>
		</author>
		<idno type="DOI">10.3390/biomedicines10040778</idno>
		<ptr target="https://doi.org/10.3390/biomedicines10040778.138" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_F4zBxcp">Biomed</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">778</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Athanasaki A, Melanis K, Tsantzali I, et al. Type 2 diabetes mellitus as a risk factor for Alzheimer&apos;s disease: review and meta-analysis. Biomed. 2022;10: 778. https://doi.org/10.3390/ biomedicines10040778. 138</note>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main" xml:id="_T7GzBRm">Cognitive dysfunction in older adults with type 2 diabetes: links, risks, and clinical implications</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sinclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abdelhafiz</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cger.2020.04.002</idno>
		<ptr target="https://doi.org/10.1016/j.cger.2020.04.002.139" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_tmJsC3U">Clin Geriatr Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="407" to="417" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sinclair A, Abdelhafiz A. Cognitive dysfunction in older adults with type 2 diabetes: links, risks, and clinical implications. Clin Geriatr Med. 2020;36: 407-17. https://doi.org/10.1016/j.cger.2020.04.002. 139</note>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main" xml:id="_kBtsgC2">Update on cognitive decline and dementia in elderly with diabetes</title>
		<author>
			<persName><forename type="first">L</forename><surname>Bordier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Doucet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Boudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bauduceau</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabet.2014.02.002</idno>
		<ptr target="https://doi.org/10.1016/j.diabet.2014.02.002.140" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_N6rFFjU">Diabetes Metab</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="331" to="337" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bordier L, Doucet J, Boudet J, Bauduceau B. Update on cognitive decline and dementia in elderly with diabetes. Diabetes Metab. 2014;40: 331-7. https://doi.org/10.1016/j.diabet.2014.02. 002. 140</note>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main" xml:id="_p7yF2qT">Correlates of quality of life in older adults with diabetes</title>
		<author>
			<persName><forename type="first">N</forename><surname>Laiteerapong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Karter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc10-2424</idno>
		<ptr target="https://doi.org/10.2337/dc10-2424.141" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_GMcSvFb">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1749" to="1753" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality of life in older adults with diabetes. Diabetes Care. 2011;34:1749-53. https://doi.org/10.2337/ dc10-2424. 141</note>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main" xml:id="_Bx2Zxsc">Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications</title>
		<author>
			<persName><forename type="first">F</forename><surname>Angeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Reboldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Poltronieri</surname></persName>
		</author>
		<idno type="DOI">10.1177/1753944715594528</idno>
		<ptr target="https://doi.org/10.1177/1753944715594528.142" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jzNzhhm">Ther Adv Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="412" to="424" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Angeli F, Reboldi G, Poltronieri C, et al. Hyper- glycemia in acute coronary syndromes: from mechanisms to prognostic implications. Ther Adv Cardiovasc Dis. 2015;9:412-24. https://doi.org/10. 1177/1753944715594528. 142</note>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main" xml:id="_tdneSgC">Stress-induced hyperglycemia: consequences and management</title>
		<author>
			<persName><forename type="first">D</forename><surname>Vedantam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Poman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Motwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Asif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Anne</surname></persName>
		</author>
		<idno type="DOI">10.7759/cureus.26714</idno>
		<ptr target="https://doi.org/10.7759/cureus.26714.143" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ypMHjyS">Cureus</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">26714</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vedantam D, Poman DS, Motwani L, Asif N, Patel A, Anne KK. Stress-induced hyperglycemia: conse- quences and management. Cureus. 2022;14: e26714. https://doi.org/10.7759/cureus.26714. 143</note>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main" xml:id="_xfcj7zT">Editorial: hyperglycemia and coronary artery diseases: physiopathological findings and therapeutic implications</title>
		<author>
			<persName><forename type="first">R</forename><surname>Marfella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Federici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Paolisso</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2022.901815</idno>
		<ptr target="https://doi.org/10.3389/fphar.2022.901815.144" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_fXRht67">Front Pharmacol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">901815</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Marfella R, Federici M, Paolisso G. Editorial: hyper- glycemia and coronary artery diseases: physio- pathological findings and therapeutic implications. Front Pharmacol. 2022;13: 901815. https://doi.org/ 10.3389/fphar.2022.901815. 144</note>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main" xml:id="_YgyJuA4">Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction</title>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryde ´n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hamstent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Herlitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Waldenstro ¨m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedel</surname></persName>
		</author>
		<idno type="DOI">10.1093/oxfordjournals.eurheartj.a015067</idno>
		<ptr target="https://doi.org/10.1093/oxfordjournals.eurheartj.a015067.145" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Edqrya3">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1337" to="1344" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Malmberg K, Ryde ´n L, Hamstent A, Herlitz J, Waldenstro ¨m A, Wedel H. Effects of insulin treat- ment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocar- dial infarction. Eur Heart J. 1996;17:1337-44. https://doi.org/10.1093/oxfordjournals.eurheartj. a015067. 145</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main" xml:id="_9vyB75c">Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ritsinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ma ˚rtensson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryde ´n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Norhammar</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(14)70088-9</idno>
		<ptr target="https://doi.org/10.1016/s2213-8587(14)70088-9.146" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_RVQj3YN">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="627" to="633" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ritsinger V, Malmberg K, Ma ˚rtensson A, Ryde ´n L, Wedel H, Norhammar A. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the ran- domised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2014;2:627-33. https:// doi.org/10.1016/s2213-8587(14)70088-9. 146</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main" xml:id="_yDGmPPh">Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ryde ´n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedel</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehi199</idno>
		<ptr target="https://doi.org/10.1093/eurheartj/ehi199.147" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_cYnzv7X">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="650" to="661" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Malmberg K, Ryde ´n L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61. https://doi. org/10.1093/eurheartj/ehi199. 147</note>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main" xml:id="_N6vZAWX">Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Arah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Terauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M ;</forename><surname>Noda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kleindorfer</surname></persName>
		</author>
		<idno type="DOI">10.2337/diacare.28.2.355</idno>
		<ptr target="https://doi.org/10.2337/diacare.28.2.355.149" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NntZUHe">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page" from="355" to="359" />
			<date type="published" when="2005">2013. 2005</date>
		</imprint>
	</monogr>
	<note>Epidemiology of ischemic stroke in patients with diabetes BMJ</note>
	<note type="raw_reference">Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:4533. https://doi.org/10. 1136/bmj.f4533. 148. Kissela BM, Khoury J, Kleindorfer D, et al. Epi- demiology of ischemic stroke in patients with dia- betes. Diabetes Care. 2005;28:355-9. https://doi. org/10.2337/diacare.28.2.355. 149</note>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main" xml:id="_7NJHWkx">Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Frankel</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.59.5.669</idno>
		<ptr target="https://doi.org/10.1212/wnl.59.5.669.150" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_SsjBuDb">Neurology</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="669" to="674" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt- PA stroke trial. Neurology. 2002;59:669-74. https:// doi.org/10.1212/wnl.59.5.669. 150</note>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main" xml:id="_rqNhY8u">Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Capes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Malmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pathak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Gerstein</surname></persName>
		</author>
		<idno type="DOI">10.1161/hs1001.096194</idno>
		<ptr target="https://doi.org/10.1161/hs1001.096194.151" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_frSmPdW">Stroke</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2426" to="2432" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients. Stroke. 2001;32: 2426-32. https://doi.org/10.1161/hs1001.096194. 151</note>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main" xml:id="_XaDJTEf">Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Krinock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Singhal</surname></persName>
		</author>
		<idno type="DOI">10.1111/nyas.14583</idno>
		<ptr target="https://doi.org/10.1111/nyas.14583.152" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bt8RZMb">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1495</biblScope>
			<biblScope unit="page" from="78" to="98" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krinock MJ, Singhal NS. Diabetes, stroke, and neu- roresilience: looking beyond hyperglycemia. Ann N Y Acad Sci. 2021;1495:78-98. https://doi.org/10. 1111/nyas.14583. 152</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main" xml:id="_jBHyU2z">Care of the patient with acute ischemic stroke (Endovascular/ Intensive Care Unit-Postinterventional Therapy): update to 2009 comprehensive nursing care scientific statement: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Abdelhak</surname></persName>
		</author>
		<idno type="DOI">10.1161/str.0000000000000358</idno>
		<ptr target="https://doi.org/10.1161/str.0000000000000358.153" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_DqVyMb6">Stroke</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="198" to="210" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rodgers ML, Fox E, Abdelhak T, et al. Care of the patient with acute ischemic stroke (Endovascular/ Intensive Care Unit-Postinterventional Therapy): update to 2009 comprehensive nursing care scien- tific statement: a scientific statement from the American Heart Association. Stroke. 2021;52:e198- 210. https://doi.org/10.1161/str. 0000000000000358. 153</note>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main" xml:id="_kWQs7wp">Current cancer therapies and their influence on glucose control</title>
		<author>
			<persName><forename type="first">C</forename><surname>Yim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mansell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hussein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Arnason</surname></persName>
		</author>
		<idno type="DOI">10.4239/wjd.v12.i7.1010</idno>
		<ptr target="https://doi.org/10.4239/wjd.v12.i7.1010.154" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_VZYdDWf">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1010" to="1025" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yim C, Mansell K, Hussein N, Arnason T. Current cancer therapies and their influence on glucose control. World J Diabetes. 2021;12:1010-25. https://doi.org/10.4239/wjd.v12.i7.1010. 154</note>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main" xml:id="_QKB5urE">Impact of hyperglycemia on the efficacy of chemotherapy-a systematic review of preclinical studies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Gerards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Van Der Velden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Baars</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.critrevonc.2017.03.007</idno>
		<ptr target="https://doi.org/10.1016/j.critrevonc.2017.03.007.155" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_CVN4VWg">Crit Rev Oncol Hemat</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="235" to="241" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gerards MC, van der Velden DL, Baars JW, et al. Impact of hyperglycemia on the efficacy of chemotherapy-a systematic review of preclinical studies. Crit Rev Oncol Hemat. 2017;113:235-41. https://doi.org/10.1016/j.critrevonc.2017.03.007. 155</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main" xml:id="_6jZUCZD">Blood glucose concentration and outcome of critical illness: the impact of diabetes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Egi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bellomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stachowski</surname></persName>
		</author>
		<idno type="DOI">10.1097/ccm.0b013e318181039a</idno>
		<ptr target="https://doi.org/10.1097/ccm.0b013e318181039a.156" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_4QpvGY6">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2249" to="2255" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Egi M, Bellomo R, Stachowski E, et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med. 2008;36: 2249-55. https://doi.org/10.1097/ccm. 0b013e318181039a. 156</note>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main" xml:id="_djyDNZX">Glucose variability is associated with intensive care unit mortality</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hermanides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Vriesendorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Zandstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Hoekstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Devries</surname></persName>
		</author>
		<idno type="DOI">10.1097/ccm.0b013e3181cc4be9</idno>
		<ptr target="https://doi.org/10.1097/ccm.0b013e3181cc4be9.157" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_ezfUErH">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="838" to="842" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hermanides J, Vriesendorp TM, Bosman RJ, Zand- stra DF, Hoekstra JB, DeVries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med. 2010;38:838-42. https://doi.org/10. 1097/ccm.0b013e3181cc4be9. 157</note>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main" xml:id="_utxyKJN">Variations of blood glucose in cancer patients during chemotherapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qi</surname></persName>
		</author>
		<idno type="DOI">10.4103/1119-3077.187323</idno>
		<ptr target="https://doi.org/10.4103/1119-3077.187323.158" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NUvwFdG">Niger J Clin Pract</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">704</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yang J, Jia B, Qiao Y, Chen W, Qi X. Variations of blood glucose in cancer patients during chemotherapy. Niger J Clin Pract. 2016;19:704. https://doi.org/10.4103/1119-3077.187323. 158</note>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main" xml:id="_qFUdXpr">The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Latham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Lancaster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Covington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Pirolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Thomas</surname></persName>
		</author>
		<idno type="DOI">10.1086/501830</idno>
		<ptr target="https://doi.org/10.1086/501830.159" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_aShK38E">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="607" to="612" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardio- thoracic surgery patients. Infect Control Hosp Epidemiol. 2001;22:607-12. https://doi.org/10. 1086/501830. 159</note>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main" xml:id="_WUUssKj">Diabetes and risk of surgical site infection: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Knott</surname></persName>
		</author>
		<idno type="DOI">10.1017/ice.2015.249</idno>
		<ptr target="https://doi.org/10.1017/ice.2015.249.160" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TaEbt94">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="88" to="99" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37:88-99. https://doi.org/10.1017/ice.2015. 249. 160</note>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main" xml:id="_4tekpgK">The impact of hyperglycemia and obesity on hospitalization costs and clinical outcome in general surgery patients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Buehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fayfman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A-S</forename><surname>Alexopoulos</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jdiacomp.2015.07.027</idno>
		<ptr target="https://doi.org/10.1016/j.jdiacomp.2015.07.027.161" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_rue4N3k">J Diabetes Complicat</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1177" to="1182" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Buehler L, Fayfman M, Alexopoulos A-S, et al. The impact of hyperglycemia and obesity on hospital- ization costs and clinical outcome in general sur- gery patients. J Diabetes Complicat. 2015;29: 1177-82. https://doi.org/10.1016/j.jdiacomp.2015. 07.027. 161</note>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main" xml:id="_qYE9jyA">Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Ruedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Riddlesworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Study</forename><surname>Diamond</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
		<idno type="DOI">10.1177/1932296817704445</idno>
		<ptr target="https://doi.org/10.1177/1932296817704445.162" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_HT7btub">J Diabetes Sci Technol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1138" to="1146" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138-46. https://doi.org/10. 1177/1932296817704445. 162</note>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main" xml:id="_JceMvtb">Newonset diabetes after kidney transplantation: incidence and associated factors</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guerra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bugalho</surname></persName>
		</author>
		<idno type="DOI">10.4239/wjd.v9.i7.132</idno>
		<ptr target="https://doi.org/10.4239/wjd.v9.i7.132.163" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_n25cc2A">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="132" to="137" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gomes V, Ferreira F, Guerra J, Bugalho MJ. New- onset diabetes after kidney transplantation: inci- dence and associated factors. World J Diabetes. 2018;9:132-7. https://doi.org/10.4239/wjd.v9.i7. 132. 163</note>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main" xml:id="_7CqCBwP">New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Vest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Cherikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Noreen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stehlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Khush</surname></persName>
		</author>
		<idno type="DOI">10.1097/tp.0000000000003647</idno>
		<ptr target="https://doi.org/10.1097/tp.0000000000003647.164" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_QZJ9fyR">Transplantation</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="178" to="187" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Vest AR, Cherikh WS, Noreen SM, Stehlik J, Khush KK. New-onset diabetes mellitus after adult heart transplantation and the risk of renal dysfunction or mortality. Transplantation. 2022;106:178-87. https://doi.org/10.1097/tp.0000000000003647. 164</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main" xml:id="_T4vxMEC">New-onset diabetes after transplantation: 2003 international consensus guidelines</title>
		<author>
			<persName><forename type="first">J</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dantal</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.tp.0000069952.49242.3e</idno>
		<ptr target="https://doi.org/10.1097/01.tp.0000069952.49242.3e.165" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_HfcpYfU">Transplantation</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="3" to="24" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation. 2003;75: 3-24. https://doi.org/10.1097/01.tp.0000069952. 49242.3e. 165</note>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main" xml:id="_6UptnBz">Patient survival after renal transplantation: IV impact of post-transplant diabetes</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Cosio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Pesavento</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Osei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Ferguson</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1523-1755.2002.kid582.x</idno>
		<ptr target="https://doi.org/10.1111/j.1523-1755.2002.kid582.x.166" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_aMaGB8G">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1440" to="1446" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal trans- plantation: IV impact of post-transplant diabetes. Kidney Int. 2002;62:1440-6. https://doi.org/10. 1111/j.1523-1755.2002.kid582.x. 166</note>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main" xml:id="_uv7ZAKX">Validation of time in range as an outcome measure for diabetes clinical trials</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Riddlesworth</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc18-1444</idno>
		<ptr target="https://doi.org/10.2337/dc18-1444.167" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_zn23Yfx">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page">181444</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2018;42: 181444. https://doi.org/10.2337/dc18-1444. 167</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main" xml:id="_hE3zB5Z">Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc18-1131</idno>
		<ptr target="https://doi.org/10.2337/dc18-1131.168" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_BzRPcyY">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">181131</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitor- ing, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41: 181131. https://doi.org/10. 2337/dc18-1131. 168</note>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main" xml:id="_kJh6WA8">Continuous interstitial glucose monitoring in nondiabetic subjects with end-stage renal disease undergoing maintenance haemodialysis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sobngwi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ashuntantang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ndounia</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2010.06.001</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2010.06.001.169" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_zErKbFn">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="22" to="25" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sobngwi E, Ashuntantang G, Ndounia E, et al. Continuous interstitial glucose monitoring in non- diabetic subjects with end-stage renal disease undergoing maintenance haemodialysis. Diabetes Res Clin Pract. 2010;90:22-5. https://doi.org/10. 1016/j.diabres.2010.06.001. 169</note>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main" xml:id="_PCY4D4b">Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Joubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fourmy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Henri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ficheux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lobbedez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Reznik</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2015.01.026</idno>
		<ptr target="https://doi.org/10.1016/j.diabres.2015.01.026.170" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_WyPNA6W">Diabetes Res Clin Pract</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="348" to="354" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Joubert M, Fourmy C, Henri P, Ficheux M, Lobbedez T, Reznik Y. Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. Diabetes Res Clin Pract. 2015;107:348-54. https://doi.org/10.1016/j.diabres. 2015.01.026. 170</note>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main" xml:id="_ZTWqvRF">Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bergenstal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Close</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc18-1581</idno>
		<ptr target="https://doi.org/10.2337/dc18-1581.171" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_6gfq5VS">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">181581</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for esti- mating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:181581. https://doi.org/10. 2337/dc18-1581. 171</note>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main" xml:id="_tXvEgzh">Glycemic monitoring and management in advanced chronic kidney disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Galindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Scioscia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Umpierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Tuttle</surname></persName>
		</author>
		<idno type="DOI">10.1210/endrev/bnaa017</idno>
		<ptr target="https://doi.org/10.1210/endrev/bnaa017.172" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_FdzgxrN">Endocr Rev</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="756" to="774" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41:756-74. https://doi.org/10.1210/endrev/ bnaa017. 172</note>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main" xml:id="_tSBYk9A">Understanding the clinical implications of differences between GMI and HbA1c</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gomez-Peralta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Choudhary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cosson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Irace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rami-Merhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seibold</surname></persName>
		</author>
		<idno type="DOI">10.1111/dom.14638</idno>
		<ptr target="https://doi.org/10.1111/dom.14638.173" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_nQkhWgq">Diabetes Obes Metab</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gomez-Peralta F, Choudhary P, Cosson E, Irace C, Rami-Merhar B, Seibold A. Understanding the clin- ical implications of differences between GMI and HbA1c. Diabetes Obes Metab. 2022. https://doi.org/ 10.1111/dom.14638. 173</note>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main" xml:id="_xHTXh84">Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Howgate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Keefe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<idno type="DOI">10.1016/s2213-8587(20)30406-x</idno>
		<ptr target="https://doi.org/10.1016/s2213-8587(20)30406-x.174" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_RRx69Nk">Lancet Diabetes Endocrinol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="153" to="164" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Murphy HR, Howgate C, O&apos;Keefe J, et al. Charac- teristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national popula- tion-based cohort study. Lancet Diabetes Endocri- nol. 2021;9:153-64. https://doi.org/10.1016/s2213- 8587(20)30406-x. 174</note>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main" xml:id="_3N8z4GF">Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Evers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>De Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gha</forename><surname>Visser</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.38043.583160.ee</idno>
		<ptr target="https://doi.org/10.1136/bmj.38043.583160.ee.175" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_CVunj9S">BMJ</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page">915</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evers IM, de Valk HW, Visser GHA. Risk of com- plications of pregnancy in women with type 1 dia- betes: nationwide prospective study in the Netherlands. BMJ. 2004;328:915. https://doi.org/ 10.1136/bmj.38043.583160.ee. 175</note>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main" xml:id="_hbSSCNH">Gestational diabetes from A to Z</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Dirar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Doupis</surname></persName>
		</author>
		<idno type="DOI">10.4239/wjd.v8.i12.489</idno>
		<ptr target="https://doi.org/10.4239/wjd.v8.i12.489.176" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_X9D2hjC">World J Diabetes</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="489" to="511" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dirar AM, Doupis J. Gestational diabetes from A to Z. World J Diabetes. 2017;8:489-511. https://doi. org/10.4239/wjd.v8.i12.489. 176</note>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main" xml:id="_JmecrVD">Identification of maternal continuous glucose monitoring metrics related to newborn birth weight in pregnant women with gestational diabetes</title>
		<author>
			<persName><forename type="first">S-Y</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>ˇurauskien _ E</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D-M</forename></persName>
		</author>
		<idno type="DOI">10.1007/s12020-021-02787-x</idno>
		<ptr target="https://doi.org/10.1007/s12020-021-02787-x.177" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_P54Rzh6">Endocrine</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="290" to="299" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shen S-Y, Z ˇurauskien _ e J, Wei D-M, et al. Identifica- tion of maternal continuous glucose monitoring metrics related to newborn birth weight in pregnant women with gestational diabetes. Endocrine. 2021;74:290-9. https://doi.org/10.1007/s12020- 021-02787-x. 177</note>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main" xml:id="_XbgpRG9">Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Law</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alnaji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alrefaii</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc18-2212</idno>
		<ptr target="https://doi.org/10.2337/dc18-2212.178" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jPxeQSs">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="810" to="815" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Law GR, Alnaji A, Alrefaii L, et al. Suboptimal noc- turnal glucose control is associated with large for gestational age in treated gestational diabetes mel- litus. Diabetes Care. 2019;42:810-5. https://doi.org/ 10.2337/dc18-2212. 178</note>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main" xml:id="_cxuhK58">Glycaemic variability and risk factors of pregnant women with and without gestational diabetes mellitus measured by continuous glucose monitoring</title>
		<author>
			<persName><forename type="first">´m</forename><surname>Ga ´borova</surname></persName>
		</author>
		<author>
			<persName><surname>Donic ˇova ´v</surname></persName>
		</author>
		<author>
			<persName><surname>Bac ˇova ´i</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph18073402</idno>
		<ptr target="https://doi.org/10.3390/ijerph18073402.179" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_WAjPtwk">Int J Environ Res Public Health</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">3402</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ga ´borova ´M, Donic ˇova ´V, Bac ˇova ´I, et al. Glycaemic variability and risk factors of pregnant women with and without gestational diabetes mellitus measured by continuous glucose monitoring. Int J Environ Res Public Health. 2021;18:3402. https://doi.org/10. 3390/ijerph18073402. 179</note>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main" xml:id="_nrcXKMf">Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and metaanalysis of randomized clinical trials</title>
		<author>
			<persName><forename type="first">A</forename><surname>Majewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Stanirowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´m</forename><surname>Wielgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´d ;</forename><surname>Bomba-Opon</surname></persName>
		</author>
		<author>
			<persName><surname>Rm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Benı ´tez-Valderrama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barquiel</surname></persName>
		</author>
		<idno type="DOI">10.1111/dme.14703</idno>
		<ptr target="https://doi.org/10.1111/dme.14703.181" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_4cQruuM">J Clin Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">14703</biblScope>
			<date type="published" when="2022">2022. 2022</date>
		</imprint>
	</monogr>
	<note>Efficacy of continuous glucose monitoring on glycaemic control in pregnant women with gestational diabetes mellitus-a systematic review Diabet Med</note>
	<note type="raw_reference">Majewska A, Stanirowski PJ, Wielgos ´M, Bomba- Opon ´D. Efficacy of continuous glucose monitoring on glycaemic control in pregnant women with gestational diabetes mellitus-a systematic review. J Clin Med. 2022;11:2932. https://doi.org/10.3390/ jcm11102932. 180. Garcı ´a-Moreno RM, Benı ´tez-Valderrama P, Barquiel B, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta- analysis of randomized clinical trials. Diabet Med. 2022;39:e14703. https://doi.org/10.1111/dme. 14703. 181</note>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main" xml:id="_tMDYzDp">Birth weight and subsequent risk of type 2 diabetes: a meta-analysis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rodekamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schellong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Dudenhausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Plagemann</surname></persName>
		</author>
		<idno type="DOI">10.1093/aje/kwk071</idno>
		<ptr target="https://doi.org/10.1093/aje/kwk071.182" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gFcqqrs">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="849" to="857" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol. 2007;165:849-57. https://doi.org/10.1093/aje/ kwk071. 182</note>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main" xml:id="_52MX3UP">Acceleration of BMI in early childhood and risk of sustained obesity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Geserick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gausche</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1803527</idno>
		<ptr target="https://doi.org/10.1056/nejmoa1803527.183" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_VuXBUG2">New Engl J Med</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="1303" to="1312" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Geserick M, Vogel M, Gausche R, et al. Acceleration of BMI in early childhood and risk of sustained obesity. New Engl J Med. 2018;379:1303-12. https://doi.org/10.1056/nejmoa1803527. 183</note>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main" xml:id="_NthxqDY">Gestational and pregestational diabetes in pregnant women with cystic fibrosis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Roe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Jagdeesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Putman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcte.2021.100289</idno>
		<ptr target="https://doi.org/10.1016/j.jcte.2021.100289.184" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_rCnxvDG">J Clin Transl Endocrinol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page">100289</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oxman R, Roe AH, Jagdeesh U, Putman MS. Gesta- tional and pregestational diabetes in pregnant women with cystic fibrosis. J Clin Transl Endocri- nol. 2022;27: 100289. https://doi.org/10.1016/j. jcte.2021.100289. 184</note>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main" xml:id="_DNqShFU">The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ashcroft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mackillop</surname></persName>
		</author>
		<idno type="DOI">10.1111/1471-0528.16423</idno>
		<ptr target="https://doi.org/10.1111/1471-0528.16423.185" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_dvJBCGz">Bjog Int J Obstetrics Gynaecol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1696" to="1703" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ashcroft A, Chapman S, Mackillop L. The outcome of pregnancy in women with cystic fibrosis: a UK population-based descriptive study. Bjog Int J Obstetrics Gynaecol. 2020;127:1696-703. https:// doi.org/10.1111/1471-0528.16423. 185</note>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main" xml:id="_VpCVKDM">Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rayman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Duffield</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc07-0500</idno>
		<ptr target="https://doi.org/10.2337/dc07-0500.186" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8jAZ6yV">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2785" to="2791" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. Diabetes Care. 2007;30:2785-91. https://doi.org/10.2337/dc07- 0500. 186</note>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main" xml:id="_w2kVqpH">Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Donovan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Corcoy</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(17)32400-5</idno>
		<ptr target="https://doi.org/10.1016/s0140-6736(17)32400-5.187" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_t4g7AsN">Lancet</title>
		<imprint>
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="page" from="2347" to="2359" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390: 2347-59. https://doi.org/10.1016/s0140- 6736(17)32400-5. 187</note>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main" xml:id="_SWT4t6v">Continuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kristensen</surname></persName>
		</author>
		<idno type="DOI">10.2337/dc22-0078</idno>
		<ptr target="https://doi.org/10.2337/dc22-0078.188" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_s6ZxeHM">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1724" to="1734" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Scott EM, Murphy HR, Kristensen KH, et al. Con- tinuous glucose monitoring metrics and birth weight: informing management of type 1 diabetes throughout pregnancy. Diabetes Care. 2022;45: 1724-34. https://doi.org/10.2337/dc22-0078. 188</note>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main" xml:id="_AFNrTsM">Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kristensen</surname></persName>
		</author>
		<author>
			<persName><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sengpiel</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00125-019-4850-0</idno>
		<ptr target="https://doi.org/10.1007/s00125-019-4850-0.189" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_mhK6vpS">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1143" to="1153" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kristensen K, O ¨gge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia. 2019;62:1143-53. https://doi.org/10.1007/s00125-019-4850-0. 189</note>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main" xml:id="_Hzn6eCp">Time in range and pregnancy outcomes in people with diabetes using continuous glucose monitoring</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Bartal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cornthwaite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ghafir</surname></persName>
		</author>
		<idno type="DOI">10.1055/a-1904-9279</idno>
		<ptr target="https://doi.org/10.1055/a-1904-9279.190" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_NSB7473">Am J Perinat</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bartal MF, Cornthwaite JA, Ghafir D, et al. Time in range and pregnancy outcomes in people with dia- betes using continuous glucose monitoring. Am J Perinat. 2022. https://doi.org/10.1055/a-1904-9279. 190</note>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main" xml:id="_RgKf8Rw">Maternal glucose variability during pregnancy &amp; birthweight percentile in women with pre-gestational diabetes</title>
		<author>
			<persName><forename type="first">N</forename><surname>Dori-Dayan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cukierman-Yaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kedar</surname></persName>
		</author>
		<idno type="DOI">10.1080/09513590.2021.1993814</idno>
		<ptr target="https://doi.org/10.1080/09513590.2021.1993814.191" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_8rWGgSK">Gynecol Endocrinol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1116" to="1120" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Dori-Dayan N, Cukierman-Yaffe T, Kedar N, et al. Maternal glucose variability during pregnancy &amp; birthweight percentile in women with pre-gesta- tional diabetes. Gynecol Endocrinol. 2021;37: 1116-20. https://doi.org/10.1080/09513590.2021. 1993814. 191</note>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main" xml:id="_Ed5qfvf">Intermittently scanned continuous glucose monitoring is associated with lower spontaneous abortion rate compared with conventional blood glucose monitoring in pregnant women with type 1 diabetes: an observational study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lemaitre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Faiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Baudoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Subtil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vambergue</surname></persName>
		</author>
		<idno type="DOI">10.1177/14791641221136837</idno>
		<ptr target="https://doi.org/10.1177/14791641221136837.192" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_2eEvH64">Diabetes Vasc Dis Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">14791641221136836</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lemaitre M, Faiz K, Baudoux F, Subtil D, Vambergue A. Intermittently scanned continuous glucose monitoring is associated with lower spontaneous abortion rate compared with conventional blood glucose monitoring in pregnant women with type 1 diabetes: an observational study. Diabetes Vasc Dis Res. 2022;19:14791641221136836. https://doi.org/ 10.1177/14791641221136837. 192</note>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main" xml:id="_guttpxd">Flash glucose monitoring in gestational diabetes mellitus: study protocol for a randomised controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Majewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stanirowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´m</forename><surname>Wielgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´d</forename><surname>Bomba-Opon</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2020-041486</idno>
		<ptr target="https://doi.org/10.1136/bmjopen-2020-041486.193" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_773gk24">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">41486</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Majewska A, Stanirowski P, Wielgos ´M, Bomba- Opon ´D. Flash glucose monitoring in gestational diabetes mellitus: study protocol for a randomised controlled trial. BMJ Open. 2021;11:e041486. https://doi.org/10.1136/bmjopen-2020-041486. 193</note>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main" xml:id="_FPR9q2d">The challenge of sustainable access to telemonitoring tools for people with diabetes in Europe: lessons from COVID-19 and beyond</title>
		<author>
			<persName><forename type="first">P</forename><surname>Choudhary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bellido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Graner</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-021-01132-9</idno>
		<ptr target="https://doi.org/10.1007/s13300-021-01132-9.194" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_jwTT7T4">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choudhary P, Bellido V, Graner M, et al. The chal- lenge of sustainable access to telemonitoring tools for people with diabetes in Europe: lessons from COVID-19 and beyond. Diabetes Ther. 2021;2:1-17. https://doi.org/10.1007/s13300-021-01132-9. 194</note>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main" xml:id="_cAyUPtW">Telemonitoring, telemedicine and time in range during the pandemic: paradigm change for diabetes risk management in the post-COVID future</title>
		<author>
			<persName><forename type="first">E</forename><surname>Commission</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Danne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Limbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Domingo</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13300-021-01114-x</idno>
		<ptr target="https://doi.org/10.1007/s13300-021-01114-x.196" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q4Cn6Wr">Diabetes Ther</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2289" to="2310" />
			<date type="published" when="2018">2018. 2021</date>
		</imprint>
	</monogr>
	<note>Benchmarking deployment of eHealth among general practitioners</note>
	<note type="raw_reference">Commission E. Benchmarking deployment of eHealth among general practitioners. 2018. 195. Danne T, Limbert C, Domingo MP, et al. Telemon- itoring, telemedicine and time in range during the pandemic: paradigm change for diabetes risk man- agement in the post-COVID future. Diabetes Ther. 2021;12:2289-310. https://doi.org/10.1007/s13300- 021-01114-x. 196</note>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main" xml:id="_MXj4my7">The imperious need for telemedicine for the care of diabetes during the COVID-19 pandemic. A comprehensive approach study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Silva-Tinoco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De La Torre-Saldan ˜a</surname></persName>
		</author>
		<idno type="DOI">10.24875/gmm.m21000563</idno>
		<ptr target="https://doi.org/10.24875/gmm.m21000563.197" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_6MP7NTW">Gac Med Mex</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="page" from="309" to="312" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Silva-Tinoco R, de la Torre-Saldan ˜a V. The imperi- ous need for telemedicine for the care of diabetes during the COVID-19 pandemic. A comprehensive approach study. Gac Med Mex. 2021;157:309-12. https://doi.org/10.24875/gmm.m21000563. 197</note>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main" xml:id="_PcurZay">A qualitative study of primary care physicians&apos; experiences with telemedicine during the COVID-19 pandemic in North-Eastern Poland</title>
		<author>
			<persName><forename type="first">K</forename><surname>Pogorzelska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Marcinowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chlabicz</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijerph20031963</idno>
		<ptr target="https://doi.org/10.3390/ijerph20031963.198" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_MaNCxFT">Int J Environ Res Public Health</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">1963</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pogorzelska K, Marcinowicz L, Chlabicz S. A quali- tative study of primary care physicians&apos; experiences with telemedicine during the COVID-19 pandemic in North-Eastern Poland. Int J Environ Res Public Health. 2023;20:1963. https://doi.org/10.3390/ ijerph20031963. 198</note>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main" xml:id="_J8czp6q">Chronic conditions patient&apos;s perception of post-COVID-19 pandemic teleconsulting continuation in primary care clinics: a qualitative descriptive study</title>
		<author>
			<persName><forename type="first">M-E</forename><surname>Poitras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-D</forename><surname>Poirier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Couturier</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2022-066871</idno>
		<ptr target="https://doi.org/10.1136/bmjopen-2022-066871" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_yW3dhHQ">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">66871</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Poitras M-E, Poirier M-D, Couturier Y, et al. Chronic conditions patient&apos;s perception of post-COVID-19 pandemic teleconsulting continuation in primary care clinics: a qualitative descriptive study. BMJ Open. 2022;12:e066871. https://doi.org/10.1136/ bmjopen-2022-066871.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
